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Abstract 
Among all brain cancers, glioblastoma multiforme (GBM) is the most common, 
malignant and lethal type of tumor. Standard treatment consists on the removal of the 
tumor mass with surgery, followed by chemotherapy and radiotherapy. Despite the recent 
advances in therapy, the life expectancy of GBM patients after diagnosis is very low. For 
this reason, new therapeutic approaches for GBM are urgently needed.  
The discovery of cancer stem cells opens the possibility for new types of therapy. Beyond 
their capacity for self-renewal and tumorigenesis, these cells are known for their high 
resistance to radiotherapy and chemotherapy, when compared to other cancer cells. Since 
these cells can remain in the tissue and form a new tumor even after treatment, it seems 
essential to develop therapeutic strategies that target cancer stem cells, with the ultimate 
goal of eradicating the tumor. In this regard, miRNAs have received special attention 
from the scientific community in recent years. A large number of studies has suggested 
that miRNAs play important roles in the development of malignant gliomas. Taking this 
into account, therapies for GBM based on miRNA modulation are a promising field of 
research.  
In this study, we proposed to isolate and characterize the glioblastoma stem cell (GSCs) 
population present in the U87 human glioblastoma cell line. Our results showed that cells 
isolated from this cell line, using magnetic CD133-microbeads, express nestin and 
CD133, two well established cancer stem cells markers, and grow in the form of 
neurospheres in low-adhesion conditions. Our second goal was to compare the miRNA 
profile of GCSs and other GBM cells and assess the potential of miRNA modulation in 
the GSCs, with therapeutic purposes. We found that CD133+ and CD133- cells showed 
different miRNA profiles, especially in what concerns miR-128 expression, since this 
miRNA was highly downregulated in CD133+ cells.  
We also evaluated the effect of miR-128 overexpression, alone or in combination with 
the drug sunitinib, in GBM tumor cell viability. These experiments allowed us to 
demonstrate that miR-128 overexpression sensitized U87 cells to sunitinib-induced cell 
death.  
Since we were unable to deliver miR-128 mimics to the GSC population using 
commercially available nucleic acid delivery systems, we developed preliminary studies 
aiming at evaluating the possibility of using stable nucleic acid delivery particles, coupled 
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to the chlorotoxin peptide, to perform miRNA modulation in these cells. We showed that 
these nanoparticles were able to deliver miRNA mimics to GSCs with high efficiency.  
Overall, we found evidences that point to an important role of miRNAs in GSC stem 
properties and that may help to clarify the contribution of these cells to tumor progression, 
paving the way to the development of new miRNA-based therapeutic strategies for GBM 
treatment.  
 
KEY WORDS: Glioblastoma multiforme, cancer stem cells, microRNAs, gene therapy, 
therapeutic resistance 
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Resumo 
Entre todos os tipos de cancro de cérebro, o glioblastoma multiforme (GBM) é o tipo de 
tumor mais comum, maligno e letal. O tratamento padrão para este tipo de cancro consiste 
na remoção do tumor através de cirurgia, seguida de quimioterapia e radioterapia. Apesar 
dos avanços recentes nas formas de terapia disponíveis para esta doença, a esperança 
média de vida após o diagnóstico dos pacientes com GBM é muito baixo. Por esta razão, 
é necessário o desenvolvimento urgente de novas abordagens terapêuticas para GBM. 
A descoberta da existência de células estaminais cancerígenas abriu a possibilidade para 
o desenvolvimento de novos tipos de terapia. Para além da sua capacidade de auto-
renovação e tumorigénese, estas células são conhecidas pela sua elevada resistência à 
radioterapia e quimioterapia, quando comparadas com outras células cancerígenas. Uma 
vez que estas células podem permanecer no tecido e formar um novo tumor, mesmo após 
o tratamento, parece essencial o desenvolvimento de estratégias terapêuticas que visam a 
eliminação das células estaminais cancerigenas, com o objetivo final de erradicar o tumor. 
A este respeito, os miRNAs tem recebido uma atenção especial por parte da comunidade 
científica nos últimos anos. Um grande número de estudos tem sugerido que os miRNAs 
podem desempenhar papéis importantes no desenvolvimento do glioblastoma e outros 
gliomas. Tendo isto em conta, as terapias contra o GBM com base na modulação miRNAs 
são um campo promissor de pesquisa. 
O objectivo principal deste trabalho consistiu no isolamento e caracterização da 
população de GSCs a partir da linha celular de glioblastoma humano U87. Os nossos 
resultados mostraram que as células isoladas desta linha cellular através do uso de 
microbeads magnéticas anti-CD133, expressavam nestina e CD133, dois marcadores bem 
estudados das GSCs, e eram capazes de crescer na forma de neuroesferas, em condições 
de não aderência. O nosso segundo objetivo passou por comparar o perfil de expressão 
de miRNAs das GCSs e de outras células de GBM, e avaliar a possibilidade de modulação 
de miRNAs nas GSC com um propósito terapêutico. As células CD133+ e as células 
CD133- mostraram diferentes perfis de expressão de miRNAs, especialmente no que diz 
respeito à expressão do miR-128, que se encontrava significantemente reduzido nas 
células CD133+.  
Também  foi avaliado o efeito da sobreexpressão do miR-128, sozinho ou em combinação 
com o fármaco sunitinib na viabilidade das células tumorais de GBM. Estas experiências 
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permitiram-nos demonstrar que o aumento dos níveis do miR-128, por si só ou em 
combinação com a droga sunitinib, sensibilizaram as células U87 para a morte celular 
induzida pelo sunitinib. 
Devido à incapacidade de entregar os oligonucelótidos miméticos do miR-128 à 
população de GSCs usando sistemas de entrega de ácidos nucleicos comerciais, 
desenvolvemos estudos preliminares visando avaliar a possibilidade de utilização de 
partículas estáveis de entrega de ácidos nucléicos, acopladas ao peptideo clorotoxina, para 
executar a modulação dos miRNAs nestas células. Mostrámos que estas nanopartículas 
são capazes de entregar os oligonucelótidos miméticos do miR-128  com elevada 
eficiência. 
Em conclusão, encontrámos evidências que apontam para um papel importante dos 
miRNAs nas propriedades estaminais das GSCs e que podem ajudar a esclarecer a 
contribuição destas células para a progressão do tumor, abrindo o caminho para o 
desenvolvimento de novas estratégias terapêuticas para GBM baseadas na modulação de 
miRNAs. 
 
PALAVRAS-CHAVE: Glioblastoma multiforme, células estaminais cancerígenas, 
microRNAs, terapia génica, resistência terapêutica 
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1.1)  Glioblastoma Multiforme 
Neurons and glia are the main cell types present in the central nervous system (CNS). 
Neurons are able to process and transmit information through electrical and chemical 
signals. Glial cells (astrocytes, oligodendrocytes and microglia) are important for neuron 
protection as well as for the metabolic and structural support of the nervous system. The 
most common malignancies in the central nervous system (CNS) are gliomas, which are 
a group of tumors that arise from glial cells1. Based on their degree of malignancy and 
genetic alterations, gliomas can be divided in four grades according to the World Health 
Organization (WHO) as is shown in table 1. Grade I gliomas, also known as Pilocytic 
Astrocytomas and Grade II gliomas have a slow growth when compared to the other 
Grades. Grade III have increased anaplasia and proliferation over grades I and II and 
present higher mortality. Grade IV is the most malignant, showing vascular proliferation 
and necrosis. Glioblastoma (GBM) also known as Glioblastoma multiforme is one of the 
deadliest tumors and has the higher occurrence between brain tumors. Glioblastoma 
multiforme (GBM) remains the most malignant and frequent (20 % of intracranial 
tumors) of gliomas, with a life expectancy of 16 months after the diagnosis, despite 
current advances in therapy1–3. The major sites for GBM occurrence are the cerebral 
hemispheres and, less commonly, the brain stem, cerebellum, and spinal cord4.  
 
Glioma Grade Observations 
Grade I (juvenile 
pilocytic astrocytoma) 
Associated with long-term survival; benign; slow-
growing tumor; less likely recurrence; low proliferative 
potential; Possibility of cure after surgical resection. 
Grade II (astrocytoma) 
Can recur as a higher grade; no necrosis; low proliferative 
potential 
Grade III (anaplastic 
astrocytoma) 
Mitosis occurs at a higher rate; no necrosis; high rate of 
recurrence; evidences of malignancy (increased mitotic 
activity) 
Grade IV 
(glioblastoma) 
Very high rate of mitosis; presence of vascular 
proliferation; necrosis; evidences of malignancy 
(mitotically very active) 
Table 1 – WHO grading system for gliomas1,3 
12 |  miRNAs expression profiling and modulation in Glioblastoma Stem Cells 
      Rúben Branco 
  
The major hallmarks of GBMs are its high ability to spread to the nearby tissue, 
uncontrolled cellular proliferation, high angiogenesis, resistance to apoptosis and genetic 
instability2. 
 
1.1.2) GBM Classification 
GBMs can be primary or secondary (figure 1), depending on the origin and development 
of the tumor. The primary or "de novo" subtype appears without prior lesions, it is more 
frequent and usually affects the elderly. The secondary or progressive subtype arises from 
lower grade astrocytomas.  Phosphatase and tensin homolog (PTEN) mutations and 
epidermal growth factor receptor (EGFR) amplification are associated with primary 
GBMs. On the other hand, tumor protein 53 (TP53) mutations are involved in the 
pathways leading to the secondary subtype5,6.  
 
 
Figure 1. Molecular genetic pathways leading to glioblastoma multiforme. GBM can be 
classified as primary or secondary depending on the characteristics and formation of the 
tumor. There are several mutations usually associated with GBM formation. For primary 
GBM, increased expression of EGFR and MDM2 and downregulation of PTEN are often 
found. The secondary pathway is more complex, usually presenting increased expression of 
PDGF/CDK4 and low expression of TP53. 
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1.1.3) GBM Hallmarks 
There are a large number of regulatory pathways which are essential to maintain the 
cellular environment, controlling the balance of cellular growth/death. In GBM, there 
several molecular variations can cause the impairment of this balance. There are different 
types of cells within the tumor, varying in morphology, genetics and biological 
behavior7,8. This heterogeneity makes this tumor particularly difficult to treat, since 
different cells respond in different ways to the available therapeutic aproaches. Tumor 
heterogeneity may arise from the accumulation of different mutations that result in 
genetic variability. Some researches suggests that this heterogeneity is due to a specific 
group of cells within the tumor, the cancer stem cells (CSCs)9–11. These authors also 
suggest that these cells are important for maintenance of the tumor self-renewal and to  
development of resistance to different types of treatment12,13. Despite recent advances in 
this field of research, the role of CSCs in GBM development and maintenance remains 
unclear.  
    1.1.3.1) Molecular Pathways involved in gliomas 
 
Neoplastic transformation of gliomas progresses through several stages of intracellular 
events: 1) acquisition of invasive properties, 2) activation of cell proliferation signals, 3) 
loss of cell cycle control, 4) upregulated angiogenesis and 5) deregulation of apoptosis. 
These hallmarks, summarized in figure 2, are due to the highly unstable genome of GBM, 
which is responsible for making it the most malignant and aggressive type of brain 
tumor7,14. 
The invasive capacity of GBM is due to its ability to migrate to nearby tissue and 
modulate the extracellular space. Glioma invasion is a complex process involving 
detachment from the original site, adhesion and remodeling of the extracellular matrix 
and cell migration15. Proteases seem to play an important role in this process. These 
proteins degrade the extracellular environment, allowing the tumor to grow and also 
promoting cell migration. Several studies show that three specific proteases are found in 
high levels in gliomas: matrix metalloproteinase 2 (MMP2), the serine protease 
urokinase-type plasminogen activator and its receptor, and the cysteine protease cathepsin 
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B7,14. Despite being highly invasive, GBM does not metastasize to other organs2. Many 
membrane proteins contribute to invasion signaling in GBM, such as tyrosine kinases 
receptors (RTKs), integrin and CD44. Amplification of the epidermal growth factor 
receptor (EGFR) gene is the most common alteration observed in this type of tumor. This 
overexpression of EGFR was shown to be associated with upregulation of multiple genes 
Figure 2. Signaling pathways altered in malignant gliomas. Sequence changes and copy 
number in three major signaling pathways associated with GBM:  a) RTK/RAS/PI3K, b) p53 and 
c) Rb. Blue indicates inactivating alterations while red indicates activating alterations. The 
percentages of tumors affected and the nature of the alteration can be seen below. Red boxes 
comprise the final percentages of glioblastomas. Adapted from 121 
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associated with invasion, including metaloproteases and collagens16. In addition, studies 
based on EFGR inhibition had successful results in delaying the invasion capacity of 
GBM14. Integrins are transmembrane heterodimers that link actin filaments of 
cytoskeleton to the extracellular matrix17. β1 subunits of integrin are important for the 
invasive capacity of gliomas. It was shown that α3β1 is over-expressed and is a key 
regulator of glioma cell migration18. In addition, CD44, a transmembrane glycoprotein, 
in highly expressed in all glioma types. In tumor cells, CD44 is cleaved inducing cell 
detachment from hyaluronic acid and promotes cell migration19. 
Strong proliferative activity is prominent is almost all GBM cases. GBM growth and 
progression depends of the activity of certain surface receptors that control internal 
signaling pathways, such as the RTKs and Serine/threonine specific protein kinase 
(STK)20. For instance, the gene PTEN, which encodes a tyrosine phosphatase, is located 
in band q23 of chromosome 10, and it was found to be inactivated in some GBM cases6. 
This protein is a tumor suppressor, acting as a regulator of the cell cycle and limiting 
cellular growth. PTEN alterations prevent the activation of the Akt/mTOR pathway and 
since Akt is one of the STKs that play an essential role in cellular proliferation, the 
inhibition of this pathway results in the deregulation of cell cycle4,14. Mutations on the 
retinoblastoma protein (RB) gene, located on chromosome 13, are also found in 
glioblastoma. The RB protein, when hyperphosforilated, can block the action of 
transcription factors, interfering with the cell cycle8,21. NF-κB, is a protein complex that 
controls cell proliferation and cell survival by regulating DNA transcription and 
regulating specific genes associated with this process. PDGF overexpression promotes 
glioma cell proliferation by aberrant activation of NF-κB in GBM7. It was shown that the 
high levels of NF-κB may be due to the inactivation of the PI3K pathway, which has been 
implicated in mediating the activation of PTEN and PDGF expression22. 
Another key feature in glioblastoma is angiogenesis. Higher vascularity is correlated with 
high malignancy and tumor aggressiveness. Vascular endothelial growth factor (VEGF) 
and its receptors are involved in glioblastoma angiogenesis. VEGFs are secreted by the 
tumor and are able to cause vascular permeability15,23. VEGF/VEGFR (VEGF receptor) 
participates also in the formation of primitive blood vessels and in the further 
development of blood vessels in gliomas21. 
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Necrosis occurs in astrocytomas when tumor cells achieved a high malignant state, 
constituting the major feature oh higher grade gliomas7,24. Many factors can cause 
necrosis, including regions of fast growing cells or vascular thrombosis. Vascular 
thrombosis occurs in most cases, due to the disorganized, tortuous and functionally 
abnormal vascular structure of  GBM and can lead to tissue hypoxia and, finally,  to 
cellular necrosis4,20. 
 
1.1.4) GBM Treatment 
The standard treatment for Glioblastoma consist in the surgical removal of the tumor, 
followed by chemotherapy and radiotherapy. However, even with the help of contrast 
agents, it is impossible to remove all cancer cells due to the ability of GBM to infiltrate 
the surrounding tissue4,21. 
One of the biggest problems related with treatment of GBM is the BBB (blood brain 
barrier), which is a structure of brain capillary endothelial cells that regulates molecular 
and cellular passage to the nervous tissue.  The amount and type of molecules that can 
reach the brain is very limited due to the tight junctions between endothelial cells and the 
absence of specific receptors25 . This greatly affect the majority of drugs available for 
cancer treatment, which cannot cross the BBB or, do not cross in efficient concentrations, 
that not cause excessive toxicity to the healthy tissue. To overcome this problem, several 
new treatment options have been proposed, based on modulation of BBB permeability or 
on the use of particles capable of overcoming this barrier25. 
Temozolomide (TMZ), an oral alkylating and chemotherapeutic agent, was first used 
1993 and has become a major agent for treating primary brain tumors following surgical 
resection and radiotherapy. It alkylates or methylates DNA, causing cancer cells to die. 
Nevertheless, GBMs are highly resistant to a single drug, suggesting that dual strategies 
involving standard chemotherapies like TMZ and pathway inhibitors might be a possible 
future direction for treating GBM26,27. For instance, TMZ together with the erlotinib, an 
EGFR inhibitor, and radiotherapy have recently been reported to improve patient 
survival26. 
Sunitinib is an orally bioavailable drug which has has been identified as an inhibitor of 
the angiogenic RTKs, such as the PDGFR, VEGFR-1 and VEGFR -2.  The simultaneous 
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inhibition of these targets leads to reduced tumor vascularization and cancer cell death 
and, finally, to tumor reduction28,29. Sunitinib treatment also produced an anti-invasive 
effect on GBM cells30. 
New therapeutic approaches, such as immune and gene therapy also has been the target 
of investigation by the scientific community (figure 3).  
 
1.1.4.1) Immunotherapy 
Immunotherapy has been showing promising results in the treatment of GBM since it was 
discovered that tumors are immunogenic, and possess tumor specific antigens. 
Treatments that involve the activation of the immune system are often used, due to the 
immunosuppressive environment of the tumor.  
Overall, there are two major ways for GBM treatment using immunotherapy. Active 
immunotherapy aims to boost the patient´s native immune response, while passive 
immunotherapy uses antibodies or activated immune cells directly targeting tumor 
cells9,31. 
For active immunotherapy, several antigens can be used, such as synthetic peptides, intact 
tumor cells and tumor protein lysates. Synthetic peptides, usually of small size, are 
injected as a vaccine in order to trigger an immune response in the patient by binding to 
MHC (Major Histocompatibility complex) class I molecules, which leads to activation 
of cytotoxic T lymphocytes. On the other hand, cell based immunotherapy uses antigen 
presenting cells activated by tumor antigens.  
Passive immunotherapy, can be further divided into three different methods. First, 
monoclonal antibodies can be directly injected in order to interact with specific antigens. 
For instance, bevacizumab is an IgG1 monoclonal antibody that binds to and neutralizes 
the vascular endothelial growth factor (VEGF) ligand, which is a tumor-associated 
protein32,33.  
A second approach is based on the use of cytokines to stimulate the immune system. In 
this kind of passive immunotherapy cytokine stimulation with IL-2 has been studied in 
wide variety of cancer32. 
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The third strategy involves the treatment with stimulated immune effector cells. In this 
kind of therapy immune cells are activated ex vivo before injection into the patients. Both 
lymphocyte-activated killer cells (LAK) and cytotoxic T lymphocytes (CTL) have been 
used9. 
Nevertheless, although immunotherapy is a promising therapeutic approach for gliomas, 
there is a need for better clinical trials to realize how far we can go with this type of 
treatment.  
 
1.1.4.2) Gene therapy 
Gene therapy is the introduction of nucleic acids on the cells, in order to replace a 
deficient gene or to modulate the expression of specific genes. This kind of therapy has 
been studied as a possibility for the treatment of tumors. It is important to choose the 
correct vector (particle that carries the nucleic acid) in order to deliver the nucleic acid to 
the right cells with few side effects. Synthetic vector research has focused on the use of 
nanoparticles.  Liposomal vectors, cell penetrating peptides and polymers, for example, 
have been used to deliver therapeutic genes.  
For the treatment of gliomas, viral vectors are usually used for the delivery of suicide and 
pro-apoptotic genes. One example is the use of the herpes simplex virus to deliver the 
timidine kinase gene, that converts the prodrug ganciclovir (GCV) into the metabolite 
deoxyguanosine monophosphate, resulting on the inhibition of the DNA polymerase 
activity34. 
Liposomal vectors have also been used to deliver therapeutic genes. These lipid-based 
vesicles possess many interesting characteristics which give them several as gene delivery 
system. For instance, they can incorporate both hydrophobic and hydrophilic drugs and 
their surface can be modified to incorporate ligands that confer specificity and modulate 
biodistribution and pharmacokinetics.  
Recently, siRNAs and miRNAs have appeared in the forefront of research for the 
treatment of GBM. These molecules can modulate the expression of specific genes at the 
post-transcriptional level. The combination of miRNA regulation with gene delivery 
strategies allows to target and modulate the expression of endogenous genes, either by 
downregulation of the gene mRNA or by the silencing a specific miRNA, aiming at 
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upregulating its target mRNAs35,36. For instance, microRNA-7 inhibits the epidermal 
growth factor receptor and the Akt pathway and is downregulated in glioblastoma. 
Therefore, the delivery of miR-7 mimics constitutes a new approach for the disease37. 
 
 
Figure 3. Therapeutic agents for glioma treatment and their molecular targets. Abbreviations: 
Ang, angiopoietin; bFGF, basic fibroblast growth factor; DLL, delta-like ligand; EGF, epidermal 
growth factor; EGFR, EGF receptor; ERK, extracellular signal-regulated kinase; FGFR, FGF 
receptor; HDAC, histone deacetylase; HGF, hepatocyte growth factor; JAK, Janus kinase; LRP, 
lipoprotein receptor-related protein; MAPK, mitogen-activated protein kinase; MEK, mitogen-
activated protein kinase kinase; mTOR, mammalian target of rapamycin; NICD, Notch 
intracellular domain; PARP, poly(ADP-ribose) polymerase; PDGF, platelet-derived growth factor; 
PDGFR, PDGF receptor; PLC, protein lipase C; PI3K, phosphatidylinositol 3-kinase; PKC, protein 
kinase C; RTK, receptor tyrosine kinase; SHH, sonic hedgehog; STAT, signal transducers and 
activators of transcription; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 
Adapted from121 
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1.2) Cancer Stem Cells 
Stem cells are a group of undifferentiated cells with special functions that occur in a large 
variety of somatic tissues. These cells are able to differentiate, self-renewal and control 
cellular homeostasis. They can form identical stem cells with the same potential for 
differentiation, thus maintaining the stem cell pool, or originate new cellular types that 
loose these characteristics Within the tumor, there are a minority of cells that share some 
characteristics with stem cells, which are called the Cancer Stem Cells (CSCs)38,39.  
The first evidence for CSCs came from myeloid leukaemia, where a group of researchers 
was able to induce leukaemia following transplantation of these cells. CSCs have the 
capacity to self-renewal and are able to generate the different type of cells that comprise 
the tumor, sustaining tumorigenesis40. Some results show that this types of cells are more 
resistant to radiotherapy and chemotherapy. The existence of these cells could be one of 
the reasons for the heterogeneity of the tumors since they can undergo aberrant 
differentiation to many different cell types41.  There are four characteristics that are often 
associated with CSCs. First, is the fact that only a small portion of cancer cells has the 
ability to perform tumorigenesis when transplanted into immunodeficient mice40. In 
addition, these cells have specific surface markers that can be used to promote their 
isolation by immunoselection. Moreover, the tumors generated from CSCs contain both 
tumorigenic and non-tumorigenic cells. Finally, CSCs can be transplanted through many 
generations, maintaining their self-renewal capacity39,42,43.  
There is one hypothesis that states that CSCs self-renewal and differentiation are 
maintained by the division of one stem cell in two different daughter cells, one similar to 
the parental cell and another that will undergo differentiation. There are some well-known 
self-renewal regulators, such as the transcriptional repressor Bmi-1 and Wnt/-catenin 
signaling pathway of the polycomb family, that have been  shown to be involved in this 
process11,13. 
 
1.2.1) Origin of CSCs 
It is accepted by most scientists in the field that CSCs are formed by mutated (epigenetic 
and genetic modifications) stem cells or progenitor cells of some organs that subsequently 
grow and differentiate to create primary tumors (Figure 4), but this area continues under 
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research. There are also some evidence of formation of CSCs from cells recruited from 
other organs11,43. 
Alteration of self-renewal pathways seems to be an important mechanism underlying 
CSCs formation. For instance, BMI-1, a transcriptional repressor and Wnt/β-catenin 
pathways, seems to be involved in the acquiring of self-renewal capacity by CSCs44.  
 
 
1.2.2) Self-Renewal and Differentiation Pathways 
It is well known that CSC have the ability to form new stem cells and maintain an intact 
potential for proliferation, expansion, and differentiation, thus the stem cell pool45. 
Molecular pathways that are important for CSCs biology are described below and 
summarized in table 2. 
The Wnt/β-catenin pathway induces proliferation of progenitor cells within gliomas and 
other types of tumors. The canonical Wnt cascade is one of critical regulators in stem 
cells. Recent studies identified the Wnt/β-catenin self-renewal pathway as an important 
Figure 4 – Possible mechanism for the formation of cancer stem cells. Stem cells have the 
ability to self-renewal and differentiate. When normal stem cells suffer mutations, they can 
originate a specific type of stem cells, the cancer stem cells. Adapted from 122 
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pathway for the maintenance of several CSC, such as breast CSCs. The observation of 
the overexpression of Wnt3a and Wnt1, Wnt ligands, in CSC supports the hypothesis that 
this pathway is important for CSC self-renewal and radioresistance46. 
The Sonic Hedgehog (SHH) pathway is a key regulatory pathway critical for the 
maintenance of several types of cells, including neural stem cells. Sonic Hedgehog 
signaling begins with the binding of Hedgehog ligands to the PTCH (Protein patched 
homolog 1) receptor. With this binding, gliotactin (Gli) signal transducers are activated 
and then translocated to the nucleus, where they regulate the transcription. This protein 
shown to contribute to the self-renewal and tumorigenic potential of CSCs, whereas its 
blockage leads to apoptosis and inhibition of migration43,45. 
Notch pathway is known to play an important role in CSC growth and differentiation. 
The Notch family of transmembrane receptors proteins comprise four members (Notch 
1–4). These receptors mediate cellular processes through the interaction with ligands 
(Jagged-1,-2, and Delta-like-1, -3, and-4). Notch-signaling is essential for the 
maintenance of somatic stem and progenitor cells by supporting self-renewal and 
suppressing differentiation43. Using γ-secretase, inhibitor of Notch pathway, it was 
possible to demonstrate the impairment of cell growth, clonogenic survival and tumor 
formation ability. Although highly important for self-renewal, some studies also suggest 
that Notch signaling is important for differentiation of CSCs into tumor-derived 
endothelium42,47.  
The PI3K/AKT/ pathway signaling pathway is involved in CSC biology, mainly on cell 
cycle progression and survival. AKT negatively regulates glycogen synthase kinase-3β 
(GSK-3β), promoting β-catenin-induced stem cell self-renewal. In some cancer types, 
such as breast cancer inhibition of the AKT pathway reduced CSC effectiveness43.  
Signal transducer and activator of transcription 3 (STAT3) activation is essential for stem 
cell differentiation and survival.  STATs can be phosphorylated by activated tyrosine 
kinase receptors, resulting in the formation of homo- and heterodimers that enter the 
nucleus and alter gene transcription. Based on inhibition strategies of STAT3 pathway 
using curcubitactin 1, researchers were able to differentiate CD133+ cells into CD133-
cancer negative cells41.   
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BMP (bone morphogenic protein) has an important role on differentiation signal on 
several cancer types, including GBM. The use of BMP4, an inhibitor of BMP signaling, 
led to a differentiation and proliferation block43. 
Table 2 – Overview of molecular pathways involved in CSC 
 
Pathway Cancer Function Ref. 
 
WNT 
Breast 
CML 
AML 
Involved in self-renewal, maintenance and 
radioresistance of cancer stem cells. 
42,44,46 
 
Sonic Hedgehog 
Breast 
Glioblastoma 
CML 
Colon 
 
Promotes self-renewal, migration and 
tumorigenesis. 
44,48,49 
 
Notch 
Colon 
Breast 
Glioblastoma 
Important in the maintenance of CSC and 
tumorigenesis. Recently has been reported 
to be involved in differentiation. 
42,43,50 
BMP Glioblastoma Inhibition of asymmetric division. 
7,10,43 
 
STAT 
 
Glioblastoma 
Pancreas 
Breast 
 
Essential for stem cell differentiation and 
survival. 
13,51 
 
PI3K/AKT 
 
Prostate 
Pancreas 
Glioblastoma 
Promotion of GSC self-renewal. 
Proliferation and survival of GSCs. 
Tumorigenesis. 
43,52 
TGF-β Glioblastoma CSC initiation and maintenance. 
22,45 
 
 
1.2.3) Resistance Mechanisms  
It is common knowledge that CSCs are more resistant to radiotherapy and chemotherapy 
compared to normal cancer cells, which allows them to remain in the tissue leading to 
tumor reappearance even after treatment50. Although the mechanisms for the 
development of cancer stem cell resistance still need to be studied in more detail. It is 
known that  enhanced DNA damage response (DDR), activation of self-renewal pathways 
and overexpression of ABC transporters play an important role in CSC resistance to 
therapies12,13,53.  
In glioblastoma, it has been shown that CD133+ cells are able to respond to radiation 
damage more efficiently and undergo less apoptosis when compared with CD133- cells54. 
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The reaction to DNA damage caused by irradiation comprises several kinases, such as the 
CHK1 and CHK2. Activation of CHK1 initiates cell cycle DNA repair and cell death to 
prevent damaged cells from progressing through the cell cycle, while CHK2 is a cell cycle 
checkpoint regulator and a tumor suppressor. These results are strengthened by the fact 
that CSCs can be sensitized by inhibition of this two kinases. Similar results were 
observed with inhibition of TGFβ and ALDH1 pathways, suggesting that these pathways 
can be also involved on CSC resistance13.   
In addition, the adenosine triphosphate-binding cassette (ABC) transporters can act as 
drug efflux pumps, working as protectors of many cell types, including CSCs. These cells 
can be sensitized by ABC transport inhibitors, such as the verapamil13.  
Recent studies have also suggested that Wnt and β-catenin signaling may contribute to 
radioresistance of cancer stem cells13.  
 
 
1.2.3.1) Therapeutic Strategies for Cancer Stem Cells 
Therapies that target specifically CSCs in order to eradicate the tumor are essential due 
to its self-renewal and tumorigenic properties, thus is important to evaluate the differences 
between CSCs and normal cancer cells. Current strategies target the bulk of the tumor 
and do not eradicate CSC completely, which is essential for the cure of the cancer since 
Figure 5 – Mechanisms of CSCs resistance to therapy. Enhanced DNA damage response 
(DDR) can be observed after irradiation in CSCs. High levels of ABC transporters are often 
associated with tumor resistance to therapy. Adapted from 13 
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CSC are implicated in the development of therapy resistance (figure 5) and in tumor 
recurrence13,42. 
Since CSC are rare among the tumors, the recognition of CSC within the tumor is the first 
challenge.  It is necessary to identify specific antigens within CSCs, and because CSC of 
the different tumors have come from different origins, to develop therapeutic strategies 
targeting different CSC populations42.  
One of the strategies for CSC treatment consists in the specific eradication of CSC 
preventing the tumor to reoccur. Ideally, in this strategy it is needed to target pathways 
uniquely used by cancer stem cells to generate the cancer cells. 
Another treatment strategy relies in the targeting of the pathways involved in CSC-
mediate resistance to therapies. For instance, CSC can be sensitized to irradiation by 
inhibition of Chk1 and Chk2, which are essential for DNA repair. TGFβR-1 kinase 
inhibitor is also able to enhance sensitivity to drugs, since TGFβ plays an important role 
in glioblastoma CSC resistance13.  
Differentiation therapy is based on the induction of CSC differentiation to make tumor 
growth unsustainable. For instance, differentiation of these cells can be induced by all-
trans retinoic acid (ATRA), associated with Notch pathway down-regulation or, 
alternatively, it can be achieved by modulating miRs that also target the Notch pathway 
in glioblastoma, such as miR-34a, miR-124 and miR-13713,55. 
Inhibition of ABC transporters, which are transporters responsible for drug efflux is also 
an available therapeutic option. High levels of ABC transporters are often associated with 
poor prognosis, suggesting that these transporters are essential for tumor resistance to 
therapies13.  
 
1.2.4) Markers  
Being hierarchically distinct populations, CSCs populations can be easily isolated via the 
expression of specific surface markers. Table 3 show some well-known CSCs markers 
for various types of tumors, such as the ubiquitous aldehyde dehydrogenase (ALDH1), 
CD133 (prominin 1), CD44 and nestin.  
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Many researches succeeded on the isolation of CSCs from glioblastoma using ALDH1, 
CD133 and CD44 as molecular markers. ALDH1 catalyzes the oxidation of aldehydes to 
carboxylic acids, having an important role in proliferation and migration.  
CD133, also known as proiminin 1, is a transmembrane glycoprotein. This protein is 
usually found in CSCs of glioblastoma, being the most used cell surface marker for the 
isolation of these cells, it was shown that knockdown of CD133 impairs self-renewal of 
CSCs, suggesting that this protein may be involved in this mechanism42. 
CD44, which is also a surface glycoprotein, is involved in cellular adhesion and migration 
and is the receptor for hyalunoran-mediated motility19,56. 
Despite their frequent use for CSC isolation, these markers have some associated 
problems. For instance, a single CSC marker may not be specific on its own and may 
need to be combined with at least a second markers to achieve good results. Another 
common problem is that markers can be valid for one separation method (for example, 
fluorescence-activated cell sorting), but not in others (for example, 
immunohistochemistry)57. Nevertheless, and despite the fact that none of this markers is 
universal for all cancer types, they provide good results in the isolation of cancer stem 
cells from different kinds or tumors. 
Table 3- Cancer stem cells specific markers in the different cancer types. 
 
 
 
 
  
 
 
 
 
 
 
Glioma Colon Breast Lung Liver Ovarian 
CD15 
CD90 
CD133 
Nestin 
ABCB5 
ALDH1 
CD24 
CD26 
CD29 
CD44 
CD133 
ALDH1 
CD24 
CD44 
CD90 
CD133 
ABCG2 
ALDH1 
CD90 
CD117 
CD133 
CD13 
CD24 
CD44 
CD90 
CD133 
CD24 
CD44 
CD117 
CD133 
43,53,57 57,58 43,57,58 58,59 57 57 
References 
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1.2.5) Role of CSCs in Glioblastoma Multiforme  
Glioblastoma multiforme is a highly aggressive and invasive tumor that displays extreme 
resistance to radiotherapy and chemotherapy and has a high rate of recurrence. Some of 
these characteristics are due to the presence of Glioma stem cells (GSCs), a group of cells 
that, similarly to other CSCs, is highly resistance to therapy and presents high capacity of 
self-renewal. These cells also share some properties with normal neural stem cells, such 
as the enhance potential for proliferation, angiogenesis and invasion. GSCs remains 
controversial because of unresolved questions related with the frequency of these cells, 
the surface markers by which they can be identified/isolated, and the nature/origin of 
these cells. 
The first evidence for GSCs came from Dirks and colleagues, who isolated cells from 
human GBM samples based on expression of the cell surface glycoprotein CD133 
(Prominin1/PROM1)60. Until today, and despite all referred drawbacks, CD133 is still 
considered the universal marker for CSC in glioblastoma. Paolo Brescia and colleagues 
demonstrated that CD133 is not only a marker for CSC, but it is also involved in the 
maintenance of the tumorigenic potential of GBM stem cells. By silencing CD133, they 
obtained a reduction of growth, self-renewal and the tumor-initiating ability of these cells. 
These results suggest that targeting CD133+  cells could be an interesting therapeutic 
approach54,61,62.  
In addition, GSCs were shown to have increased expression of nestin, an intermediate 
filament protein expressed in neural stem cells. The hallmarks of Nestin+ cells are 
proliferation, migration and a broad differentiation potential10,63,64. 
Many researches have shown that GCSs contribute to therapeutic resistance and, as a 
consequence, to GBM recurrence. By measuring the activating phosphorylation of several 
critical checkpoint proteins in DNA response (ATM, Rad17, Chk2 and Chk1) Bao and 
colleagues demonstrate that GCS are more resistant to radiation when compared to the 
non-stem glioma cells10. GCSs can be sensitized to radiotherapy with γ-secretase, a notch 
pathways inhibitor, suggesting that this pathway plays a role on GCS resistance10.  
Strong angiogenic activity is another of the major hallmarks of glioblastoma where GSCs 
seem to be involved. High expression of pro-angiogenic factor, vascular endothelial 
growth factor (VEGF), found in GCS, suggests that these cells play a role in angiogenic 
processes associated with glioblastoma10,15.   
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Hypoxia, another hallmark of glioblastoma, increases the expression of GSC markers and 
self-renewal indicators, suggesting that the cancer stem cell-like phenotype can be 
promoted by the micro-environment conditions found in the tumors. Focusing on the 
hypoxic niches, disrupting the GCS microenvironment can be a new approach for 
therapeutic strategies focusing GCSs13,65,66.  
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1.3) miRNAs 
Gene expression is a complex process by which the information from a gene is translated 
into the synthesis of a functional gene product, usually a protein. Along this biological 
process, regulators of gene transcription and translation operate at multiple levels in order 
to optimize the genome end products. One of the most significant advances in gene 
regulation has been the discovery of small (20–30 nucleotides) noncoding RNAs that 
regulate genes and genomes. This regulation can occur at the level of chromatin structure, 
chromosome segregation, transcription, RNA processing, RNA stability and 
translation67–69. Different classes of small RNAs have emerged and can be categorized in 
three major types: short interfering RNAs (siRNAs), microRNAs (miRNAs), and piwi-
interacting RNAs (piRNAs)69.  
SiRNAs, a class of double-stranded RNA, are involved in the RNA interference pathway, 
where they interfere with the expression of specific genes to which they present 
complementary nucleotide sequences. SiRNAs cause mRNA to be degraded after 
transcription, therefore preventing protein synthesis67.  
MicroRNAs (miRNAs) are small noncoding RNAs with ~21–23 nucleotides that act as 
regulators of gene expression in multicellular eukaryotes. These small RNA molecules 
were discovered for the first time in 1993 in Caenorhabditis elegans by Lee et al., and 
are now described to be involved in many cellular processes such as the regulation of 
signaling pathways, apoptosis, metabolism and brain development. MicroRNAs enhance 
the cleavage or translational repression of specific mRNAs that contain miRNA binding 
site(s) in their 3’untranslated region (3´UTR). Some studies indicate that miRNAs can 
control most of the protein-coding genes, being involved in almost every biological 
pathway67–69. Therefore, deregulation of miRNAs is described to play and important role 
in many diseases, including cancer68.    
  
1.3.1) Biogenesis 
MicroRNA loci are located in intronic regions of protein-coding and noncoding genes 
and also in exons of long ncRNA (non-coding RNA) transcripts70. Starting from the 
chromosome, miRNA synthesis is highly regulated from the nucleus to the cytoplasm to. 
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MicroRNA biogenesis proceeds according to has two major pathways: canonical and 
non-canonical 71(figure 6).  
 
1.3.1.1) Canonical Pathway  
Most mammalian miRNAs are transcribed from the genome by RNA polymerase II, 
generating a primary miRNA (pri-miRNA) transcript that consists of one or more hairpin 
structure72,73. These pri-miRNAs are enclosed in introns of RNA polymerase II transcripts 
(intronic miRNAs) or can be transcribed from independent miRNA genes (exonic 
miRNAs). Pri-miRNAs can be polyadenylated and caped after transcription. After 
transcription, pri-miRNAs are processed by Drosha (an RNase III enzyme present in the 
nucleus) and by the dsRNA-binding protein DGCR8 (also known as Pasha in 
invertebrates). The resulting product of this processing is a molecule of RNA with 70 
nucleotides called pre-miRNA. Pre-miRNAs are transported to the cytoplasm by exportin 
5, in a GTP-dependent process. In the cytoplasm, pre-miRNAs are cleaved by 
endonuclease DICER and the RNA-binding protein TAR (TRBP)74,75. After processing 
by the DICER/TRBP protein complex, the resulting product is one hairpin structure with 
20-23 nucleotides. Following their processing, miRNAs are assembled into 
ribonucleoprotein (RNP) complexes called micro-RNPs (miRNPs) or miRNA-induced 
silencing complexes (miRISCs)72,73. The key components of miRNPs are proteins of the 
Argonaute (AGO) family.  In mammals, four argonaute proteins have been characterized 
(AGO1 to AGO4)75.  
 
1.3.1.2) Non-Canonical Pathway 
  
Drosha mediated processing of pri-miRNAs into pre-miRNAs is not obligatory. In the 
non-canonical pathway, discovered and characterized in 2007 by Sibley and colleagues, 
miRNA precursors are produced via splicing and are called mirtrons76. These RNA 
molecules are splicing-produced short-hairpin introns with equivalent hallmarks of pre-
miRNAs. Mirtrons are transported to the cytoplasm by exportin 5 in a similar process to 
that occurring in the canonical pathway76. Due to the similar characteristics of mirtrons 
and pre-miRNAs, mirtrons are able to enter the canonical miRNA-processing pathway73. 
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Figure 6. Biogenesis of miroRNAs and their assembly into microribonucleoproteins. The 
canonical pathway starts with the production of precursor miRNAs (pre-miRNAs) by Drosha-
mediated cleavage of primary miRNA transcripts (pri-miRNA). The non-canonical pathway, starts 
with the production of pre-miRNAs by splicing-mediated cleavage of short-hairpin introns 
(mirtrons). After their processing, miRNAs are assembled into ribonucleoprotein (RNP) complexes 
(miRNPs) or miRNA-induced silencing complexes (miRISCs). The key components of miRNPs 
are proteins of the Argonaute (AGO) family. In mammals, four AGO proteins (AGO1 to AGO4) 
function in the miRNA repression pathway, but only AGO2 functions in RNAi pathway and leads 
to direct mRNA cleavage. DGCR8: DiGeorge syndrome criticical region gene 8 protein; TRBP: 
RNA-binding protein TAR; Adapted from 72 
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1.3.2) MicroRNA Mechanisms for Translational Repression  
  
Gene silencing by miRNAs may occur either via mRNA degradation or translation 
blockage. Protein levels of the target gene are consequently reduced, whereas messenger 
RNA levels may or may not be decreased77. 
Despite the imperfect pairing of miRNAs with their targets, there is a region of perfect 
base pairing comprising the nucleotides 2–8 of the miRNA. This regions represents the 
‘seed’ region, which is essential for the miRNA/mRNA interaction. MicroRNA-binding 
sites in mRNAs are located in the 3′ UTR and are usually present in multiple copies. A 
high degree of complementarity between miRNAs and sequences on the 3’ UTR of the 
target mRNA is essential for gene silencing mediated by miRNAs70,78. 
Initiation, elongation and termination are the three steps of mRNA translation. Initiation 
starts with the recognition of the mRNA 5′-end and its cap structure (7-methylguanosine, 
m7GpppN) by the eIF4E subunit of the eukaryotic translation initiation factor (eIF) 
eIF4E72. This initiation factor contains eIF4G, which is essential for the assembly of the 
ribosome initiation complex. EIF4G, with the help of eIF3, facilitates the recruitment of 
the 40S ribosomal subunit to mRNA. The 60S subunit is then attached to the small subunit 
to start mRNA translation. There is substantial evidence that suggest that miRNPs 
interfere with the eIF4E–eIF4G interaction, which prevents the assembly of the 40S 
initiation complex. An alternative theory suggests that miRNPs are able to repress 
translation by preventing 60S subunit from joining 40S74,77.  
 
 Figure7. Mechanisms of miRNA-mediated inhibition of protein translation in animals. 
MiRNP-mediated translational repression can occur at either initiation or post-initiation steps. 
The miRNP complex inhibits translation initiation by either interfering with 5’ cap (m7G) 
recognition and 40S small ribosomal subunit recruitment or antagonizing 60S subunit joining 
and preventing 80S ribosomal complex formation. Additionally, the miRNP complex inhibits 
translation at post-initiation steps by inhibiting ribosome elongation. ORF: Open reading 
frame; eIF4E: eukaryotic translation initiation factor (eIF) eIF4E; miRNPs: ribonucleoprotein 
complexes. Adapted from 72 
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The mechanism by which miRNAs repress translation does not focus exclusively in the 
initiation step. Several theories state that MiRNAs can also repress mRNA translation at 
the post-initiation steps. For example, MicroRNAs might slow the process of elongation, 
promote the degradation of the polypeptide or cause the detachment of the ribosomes 
during the process of translation70.  
 
1.3.3) Biology of miRNAs in Gliomas 
Most cellular processes are affected by miRNAs. In invertebrates, miRNAs regulate 
development, neuronal differentiation, cell proliferation, growth control, and apoptosis. 
In mammals, miRNAs have are important for embryogenesis and stem cell maintenance, 
hematopoietic cell differentiation and brain development. In most human diseases, 
including cancer, miRNA expression has been found to be deregulated, suggesting that 
these small RNA molecules may be involved is these syndromes68,79. Malignant tumors 
and tumor cell lines were found to have widespread deregulated miRNA expression 
compared to normal cells. However, in most cases it is not clear whether the altered 
miRNA expression observed in cancer is a cause or consequence of malignant 
transformation77.   
Many studies identified the importance of miRNAs in human glioma, where a significant 
number of miRNAs have been found to be deregulated and contribute to disease 
development and progression. MicroRNAs modulate most glioma cellular functions such 
as proliferation, invasion, migration, angiogenesis, resistance to therapy and 
apoptosis42,80. Table 4 shows several miRNAs that are deregulated in GBM, as well as 
some of their validated targets. 
 
1.3.3.1) MicroRNAs altered in Gliomas and their role on Gliomagenesis and Glioma 
Stem Cells 
Global analysis of miRNA expression profiles in glioblastoma cell lines allowed to 
identify miRNAs with significantly altered expression in this type of tumor and which 
contribute to making it more aggressive and proliferative81–83. 
In this regard, miR-137 (downregulated in glioblastoma) targets and suppresses CDK6 
expression, a positive mediator of cell cycle progression. Its downregulation enhances 
glioma cell proliferation, and lower miR-137 levels are associated with a poorer 
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prognosis. Studies using glioblastoma cell lines, showed that transfection of mic  roRNA-
137 also induced G1 cell cycle arrest, suggesting that this miRNA´s downregulation in 
glioblastoma could be important for its active proliferation84.  
MicroRNA-34a, also downregulated in gliomas, targets the mRNAs of multiple growth-
promoting genes, including E2F transcription factor 1 (E2F1), hepatocyte growth factor 
receptor (c-met), and CCND1. These proteins are important for sustaining the growth of 
glioma cells, and since miRNA-34a will repress their translation, the control of the tumor 
growth will be impaired85. Recently, it was also shown for the first time that miR-34a 
expression induces glioma stem cell differentiation. In the study, transfection of miR-34a 
into glioma cells led to a decrease in the immunostaining of stem cell markers CD133 and 
nestin86. 
Two other microRNAs involved in GBM, miR-181 and miR-153 promote apoptosis by 
targeting B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) mRNA and 
repressing its translation, thus inhibiting gliomagenesis. Both miR-181 and miR-153 
expression is decreased in glioma cell lines, suggesting that these two miRNAs have an 
important role in glioma by diminishing its programmed cellular death87.  
MicroRNA-128 is another well-known miRNA downregulated in glioblastoma. This 
miRNA has multiple targets of interest, including E2F3a, a transcription factor that 
induces the expression of genes involved in cell cycle progression, and Bmi-1, a member 
of the polycomb repressor complex (PRC1) involved in stem cell renewal85. BMI, a 
protein involved in stem cell self-renewal, was the first validated target for miRNA-12888. 
Upon miR-128 induction, this protein was found to be downregulated. Xiaozhong Peng 
and colleagues, using a luciferase reported assay, showed that E2F3a was negatively 
regulated by miR-128. This results present strong evidence that miR-128 can inhibit the 
proliferation of glioma cells through negatively regulating one of its targets, E2F3a, 
which is highly expressed in glioma and important for cell cycle progression89.  More 
recently, a group of researchers showed that MicroRNA-128 coordinately targets 
polycomb repressor complexes (PRC) in glioma stem cells90. The Polycomb Repressor 
Complex (PRC), an epigenetic regulator of transcription, is mediated by 2 protein 
complexes, PRC1 and PRC2. This complex has high oncogenic potential in glioblastoma, 
where it is involved in cancer stem cell maintenance and radioresistance. In this study, 
the authors showed that miR-128 simultaneously targets important constituents of PRC 1 
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and 2 and that its downregulation in glioblastoma contributes to a high level of expression 
of these proteins compared with normal brain cells.  In addition, miR-128 expression 
increases radiosensitivity of GSCs by preventing the radiation-induced increase of 
expression of PRC components, possibly by impairing DNA repair90. 
MiR-7 is an intronic miRNA, also downregulated in gliomas, which targets EGFR, a 
receptor known to be upregulated in 45% of malignant gliomas.  Besides EGFR, recent 
studies showed that miRNA-7 also targets IRS-1 and IRS-2, two important regulators of 
the AKT pathway91. Moreover, transfection with miR-7 oligonucleotides was shown to 
decreased the viability and invasiveness of primary glioblastoma cell lines37.  
Contrarily to the above mentioned miRNAs, miR-10b, which is highly expressed in a 
number of cancers and has an important role in tumor growth and metastasis, was found 
to be upregulated in GBM. MicroR-10b inhibits the translation of the mRNA encoding 
HOXD10, which modulates many genes that promote invasion, migration, extracellular 
matrix remodeling and tumor progression, including uPAR, RhoC, integrin, βintegrin and 
matrix metalloprotease-14 (MMP-14)92. Recent studies have found that inhibiting the 
expression of miR-10b reduces GBM cell growth and significantly decreases GSC 
proliferation, migration and invasion93. 
MicroRNA-221 and miRNA-222, also upregulated in glioblastoma, have been reported 
to regulate cell growth and cell cycle progression by targeting p27 and p5780. In their 
study in 2010, Chun-Sheng Kang and colleagues demonstrated for the first time that miR-
221/222 directly regulate apoptosis in glioblastoma by targeting PUMA. These miRNAs 
negatively regulate PUMA, which leads to a decrease in anti-apoptotic Bcl2 and to an 
increase in pro-apoptotic BAX94.  
MiR-21, which is the most studied miRNA in glioma, has been consistently reported to 
be upregulated in these tumors. The validated targets of miR-21 include p53, a tumor 
suppressor protein, and TGF-β, a protein that controls cellular proliferation and 
differentiation 95,96.  MicroRNA-21 also promotes glioma invasion by targeting matrix 
metalloproteinase regulators, such as the RECK, a membrane-anchored regulator, and 
TIMP3, the ECM-bound protease regulator97. These targets suggest that miR-21 has 
oncogenic potential, negatively regulating tumor suppressor functions. 
MicroRNA-221 and miRNA-222, also upregulated in glioblastoma, have been reported 
to regulate cell growth and cell cycle progression by targeting p27 and p5780. In their 
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study in 2010, Chun-Sheng Kang and colleagues demonstrated for the first time that miR-
221/222 directly regulate apoptosis in glioblastoma by targeting PUMA. These miRNAs 
negatively regulate PUMA, which leads to a decrease in anti-apoptotic Bcl2 and to an 
increase in pro-apoptotic BAX94.  
MicroRNA-26a suppresses PTEN, RB1 and MAP3K2/MEKK2 expression98. In 2013, 
Bing-Hua Jiang and colleagues showed that miR-26a directly targeted prohibitin (PHB) 
in glioma cell lines. This protein has been implicated in the regulation of proliferation, 
apoptosis, transcription and mitochondrial protein folding99. In their study, the authors 
present evidence that miR-26a regulates PHB and promotes glioma progression and 
angiogenesis100. 
MicroRNA-451 has also been found to be overexpressed in GBM cells and may function 
as an oncogene. MiRNA-451 modulates the AMPK pathway by controlling expression 
of its upstream activator, LKB1, via direct regulation of CAB39 expression 85,101 
In conclusion, over the past years, a large number of studies has suggested that miRNAs 
can play important roles in the development of malignant gliomas. Figure 8 summarizes 
the major miRNA-targeted approaches evaluated so far for GBM. These small RNA 
molecules may have their expression deregulated during tumor development and 
progression, which makes them interesting molecules to explore as potential diagnostic 
and prognostic biomarkers. In addition, the development of glioma-directed therapies 
based on miRNAs is also a promising field, posed to have a huge impact in healthcare, if 
the challenges common to all gene therapy approaches can be overcome80,87 
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Table 4 - MiRNAs deregulated in glioblastoma and their verified targets 
MicroRNA Regulation Targets References 
miR-7 Downregulated EGFR, IRS-1,  IRS-2 35,37,91 
miR-10b Upregulated HOXD10, MMP-14 35,91,93,102 
miR-21 Upregulated p53, TGF-β, RECK, TIMP3 35,86,103,104 
miR-34a Downregulated E2F1, CCND1, c-MET, CDK6 80,85,91 
miR-26a Upregulated 
PTEN, RB1, 
MAP3K2/MEKK2 PHB 
35,98,100 
miR-128 Downregulated E2F3a, PRC, BMI 85,89,105,106 
miR-137 Downregulated CDK6 84,91,107 
miR-153 Downregulated Bcl-2 79,88,91 
miR-181 Downregulated Bcl-2 91,106 
miR-221/222 Upregulated p27, p57, PUMA 94 
miR-451 Upregulated CAB39, PI3K/Akt 101,108 
 
 
38 |  miRNAs expression profiling and modulation in Glioblastoma Stem Cells 
      Rúben Branco 
  
 
 
 
 
 
 
 
 
 
 Figure 8. MiRNA-targeted therapies in GBM. Figure 8. MiRNA-targeted therapies in 
GBM. MiRNA-based therapeutic approaches for glioblastoma include the delivery, using 
different kinds of nanosystems, of miRNA mimics, designed to upregulate certain tumor 
suppressor miRNAs or anti-miRNA oligonucleotides, such as antagomiRs, antisense 
molecules or miRNA masks, developed to downregulate specific oncogenic miRNAs. 
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2) Objectives 
 
The major objectives of this work were: 
 To isolate and characterize cancer stem cells from the human glioblastoma cell line 
U87. 
 To understand the role of cancer stem cells on the maintenance and growth of 
glioblastoma multiforme. 
 To evaluate and compare the miRNA profile of glioblastoma stem cells with respect 
to differentiated glioblastoma tumor cells. 
 To evaluate the role of specific miRNAs, particularly deregulated in glioblastoma 
stem cells, in tumor cell viability and resistance. 
 To evaluate the therapeutic potential of miRNA modulation strategies, alone or in 
combination with the drug sunitinib, in tumor cell proliferation and viability. 
 To assess the possibility of glioblastoma stem cell transfection using targeted lipid-
based nucleic acid delivery systems. 
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3.1) Materials 
Sunitinib was kindly donated by Pfizer (Basel, Switzerland). Stock solutions were 
prepared in DMSO (Sigma, Germany) and stored at -20ºC. Custom-designed miRNA 
PCR plates (Pick&Mix miRNA PCR panels) were acquired from Exiqon. Primers for 
miRNA-128 and controls were acquired from Exiqon. CD133 human MicroBeads Kit 
was acquired from Miltenyi Biotec (Madrid, Spain). Lipofectamine RNAiMAX was 
acquired from Invitrogen. The list of antibodies used is shown in table 5. 
 
Table 5 – List of antibodies. 
 
 
 
 
 
3.2) Cell lines and culture conditions 
The U87 human glioma cell line was maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 4.5 g/L glucose (Invitrogen, Carlsbad, CA, USA) and 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Paisley, 
Scotland), 100 μg/mL streptomycin (Sigma), 100 U/mL penicillin (Sigma) and 10 mM 
HEPES. The cells were cultured at 37°C under a humidified atmosphere containing 5% 
CO2. Cancer stem cells were maintained in DMEM/F12 supplemented with B27 1x and 
0.02 µg/mL FGF/EGF. 
 
3.3) Isolation of CD133+ cells 
Cells were dissociated and ressuspended in PBS containing 0.5% bovine serum albumin 
and 2 mmol/L EDTA. For magnetic labeling, CD133/1 microbeads were used (Miltenyi 
Biotech). Microbeads were incubated with a maximum of 12.5 million cells for 30 min 
before magnetic separation (10µL of beads per 106 cells). Positive magnetic cell 
Antibody Company 
Alexa-488 Life Technologies 
Nestin Sigma (N5413) 
CD133-PE Miltenyi Biotec 
CD133 Enogene (E10-30240). 
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separation (MACS) was done using several MACS columns in series. During the process, 
cells within the columns were washed three times, and were finally eluted after removal 
from the magnetic field. After isolation, CD133+ cells were maintained in DMEM/F12 in 
a non-adherent environment, supplemented with B27 1x and 0.02 µg/mL FGF/EGF. 
Cd133- cells were maintained in DMEM.  
3.4) Evaluation of cell viability 
In the different experiments, cell viability was measured using the Alamar Blue assay. 
Briefly, 24 h after transfection U87/CD133+ cells were incubated with DMEM containing 
10% (v/v) of resazurin (Sigma, Munich, Germany). The absorbance of the medium was 
measured at 570 and 600 nm following 1 h of incubation at 37oC. Cell viability was 
calculated as a percentage of non-transfected control cells using equation 1. 
 
ABS570 and ABS600 are the absorbance of the transfected cells, and ABS*570 and ABS*600 
correspond to the absorbance of control cells at the indicated wavelengths. 
 
3.5) RNAi-Lipofectamine RNAiMAX complexes preparation and cell 
transplantation. 
For cellular transfection, we used Lipofectamine RNAiMAX (Invitrogen) according to 
the instructions provided by the manufacturer. For adherent cells, one day before 
transfection, cells were plated in 24-well plates with 500 μl of DMEM. On the day of 
transfection (50% cellular confluence), we prepared miRNA mimic duplex-
Lipofectamine RNAiMAX complexes. First, we diluted 5 pmol of RNAi in 50 μl 
OptiMEM without serum, followed by the dilution of 1 μl of Lipofectamine RNAiMAX 
in 50 μl of OptiMEM. Finally, the diluted RNAi and the diluted Lipofectamine were 
combined and incubated for 20 min at room temperature, forming the RNAi-
Lipofectamine RNAiMAX complexes. These complexes were added to each well 
containing cells and incubated 24-48 hours at 37°C in a CO2 incubator. For suspension 
(Equation 1) 
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cells, we used the same protocol with a few changes. In this case, we used 6-well 
multiwell plates and the RNAi-Lipofectamine RNAiMAX complexes were formed with 
30 pmol of RNAi in 150µl of OptiMEM. 
 
 3.6) RNA extraction and cDNA synthesis 
Total RNA, including small RNA species, was extracted from U87CD133-/U87 CD133+ 
cells using the miRCURY Isolation Kit – Cells (Exiqon), according to the 
recommendations of the manufacturer for cultured cells. Briefly, after cell lysis, the total 
RNA was adsorbed to a matrix, washed with the recommended buffers and eluted with 
35 μL RNase-free water by centrifugation. After RNA quantification, cDNA conversion 
for miRNA quantification was performed using the Universal cDNA Synthesis Kit 
(Exiqon). For each sample, cDNA for miRNA detection was produced from 20 ng total 
RNA, according to the following protocol: 60 min at 42oC followed by heat-inactivation 
of the reverse transcriptase for 5 min at 95oC. The resulting cDNA was diluted 40 times 
with RNase-free water before quantification by qPCR.  
Synthesis of cDNA for mRNA quantification was performed using the NZY First-Strand 
cDNA Synthesis Kit (NZYtech, Lisbon, Portugal) employing 1 μg total RNA for each 
reaction, by applying the following protocol: 10 min at 25oC, 30 min at 50oC and 5 min 
at 85oC. After transcription, the samples were further incubated for 20 min at 37oC with 
an RNase H (from E. coli) to specifically degrade the RNA template in cDNA:RNA 
hybrids after first-strand cDNA synthesis. Finally, the obtained cDNA was diluted 10 
times with RNase-free water before quantification by qRT-PCR. 
 
3.7) Quantitative Real-time PCR 
Quantitative real time PCR was performed in a StepOnePlus thermocycler (Applied 
Biosystems) using 96-well microtitre plates.  
For microRNA quantification the miRCURY LNATM Universal RT microRNA PCR 
system (Exiqon) was used in combination with pre-designed primers (Exiqon) for miR-
128. The small nuclear RNA snord44 was used as reference. A master mix was prepared 
for each primer set, according to the recommendations for real-time PCR setup of 
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individual assays suggested in this kit. For each reaction, 6 μL of master mix was added 
to 4 μL template cDNA. All reactions were performed in duplicate (two cDNA reactions 
per RNA sample) at a final volume of 10 μL per well, using the StepOnePlus software 
(Applied Biosystems). The reaction conditions consisted of polymerase 
activation/denaturation and well factor determination at 95oC for 10 min, followed by 45 
amplification cycles at 95oC for 10s and 65oC for 1 min. 
For mRNA quantification, the iQ SYBR Green Supermix Kit (Bio-Rad) was used. The 
primers for the target gene BMI and for the reference gene HPRT were pre-designed by 
Qiagen (QuantiTect Primer, Qiagen, Hilden, Germany). A master mix was prepared for 
each primer set, containing a fixed 6.5 μL volume of SYBR Green Supermix and the 
appropriate amount of each primer to yield a final concentration of 150 nM. For each 
reaction, 10 μL of master mix were added to 2.5 μL of template cDNA. All reactions were 
performed in duplicate (two cDNA reactions per RNA sample) at a final volume of 12.5 
μL per well, using the StepOnePlus software (Applied Biosystems). The reaction 
conditions consisted of enzyme activation and well-factor determination at 95oC for 1 
min and 30 s, followed by 40 cycles at 95oC for 10 s (denaturation), 30 s at 55oC 
(annealing), and 30 s at 72oC (elongation).  
For both miRNA and mRNA quantification, a melting curve protocol was started 
immediately after amplification and consisted of 1 min heating at 55oC followed by 80 
steps of 10 s, with a 0.5oC increase at each step. The miRNA and mRNA fold change 
with respect to control samples was determined by the Pfaffl method, taking into 
consideration the different amplification efficiencies of all genes and miRNAs analyzed 
in each experiment. The amplification efficiency for each target or reference RNA was 
determined according to the formula: E = 10(-1/S) – 1, where S is the slope of the obtained 
standard curve. 
 
3.8) MiRNA PCR panel 
MicroRNA quantification using the 96-well miRNA PCR plates (Exiqon) was performed 
in an iQ5 thermocycler using the SYBR® Green Master Mix (Exiqon). The primers for 
the target miRNAs are displayed in table 6.  
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Table 6 – Target sequence of miRNAs detected using the miRNA PCR plates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
microRNA Name Target sequence 
hsa-let-7b UGAGGUAGUAGGUUGUGUGGUU 
hsa-miR-101 UACAGUACUGUGAUAACUGAA 
hsa-miR-106a AAAAGUGCUUACAGUGCAGGUAG 
hsa-miR-106b UAAAGUGCUGACAGUGCAGAU 
hsa-miR-10b UACCCUGUAGAACCGAAUUUGUG 
hsa-miR-124 UAAGGCACGCGGUGAAUGCC 
hsa-miR-128 UCACAGUGAACCGGUCUCUUU 
hsa-miR-130a CAGUGCAAUGUUAAAAGGGCAU 
hsa-miR-130b CAGUGCAAUGAUGAAAGGGCAU 
hsa-miR-132 UAACAGUCUACAGCCAUGGUCG 
hsa-miR-135b UAUGGCUUUUCAUUCCUAUGUGA 
hsa-miR-148a UCAGUGCACUACAGAACUUUGU 
hsa-miR-149 UCUGGCUCCGUGUCUUCACUCCC 
hsa-miR-17 CAAAGUGCUUACAGUGCAGGUAG 
hsa-miR-181a AACAUUCAACGCUGUCGGUGAGU 
hsa-miR-181c AACAUUCAACCUGUCGGUGAGU 
hsa-miR-185 UGGAGAGAAAGGCAGUUCCUGA 
hsa-miR-188-5p CAUCCCUUGCAUGGUGGAGGG 
hsa-miR-19b UGUGCAAAUCCAUGCAAAACUGA 
hsa-miR-123 UCCUUCUGCUCCGUCCCCCAG 
hsa-miR-200c UAAUACUGCCGGGUAAUGAUGGA 
hsa-miR-203 GUGAAAUGUUUAGGACCACUAG 
hsa-miR-20a UAAAGUGCUUAUAGUGCAGGUAG 
hsa-miR-21 UAGCUUAUCAGACUGAUGUUGA 
hsa-miR-210 CUGUGCGUGUGACAGCGGCUGA 
hsa-miR-25 CAUUGCACUUGUCUCGGUCUGA 
hsa-miR-26a UUCAAGUAAUCCAGGAUAGGCU 
hsa-miR-27a UUCACAGUGGCUAAGUUCCGC 
hsa-miR-29b UAGCACCAUUUGAAAUCAGUGUU 
hsa-miR-30a UGUAAACAUCCUCGACUGGAAG 
hsa-miR-30c UGUAAACAUCCUACACUCUCAGC 
hsa-miR-32 UAUUGCACAUUACUAAGUUGCA 
hsa-miR-328 CUGGCCCUCUCUGCCCUUCCGU 
hsa-miR-34a UGGCAGUGUCUUAGCUGGUUGU 
hsa-miR-367 AAUUGCACUUUAGCAAUGGUGA 
hsa-miR-448 UUGCAUAUGUAGGAUGUCCCAU 
hsa-miR-451 AAACCGUUACCAUUACUGAGUU 
hsa-miR-566 GGGCGCCUGUGAUCCCAAC 
hsa-miR-573 CUGAAGUGAUGUGUAACUGAUCAG 
hsa-miR-623 AUCCCUUGCAGGGGCUGUUGGGU 
hsa-miR-7 UGGAAGACUAGUGAUUUUGUUGU 
hsa-miR-9 UCUUUGGUUAUCUAGCUGUAUGA 
hsa-miR-92a UAUUGCACUUGUCCCGGCCUGU 
hsa-miR-93 CAAAGUGCUGUUCGUGCAGGUAG 
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A master mix was prepared for each sample, containing equal volumes (1:1) of SYBR 
Green master mix and diluted cDNA. For each reaction, performed in duplicate, 10 μl of 
master mix were added per well. Reaction conditions and melting curve protocol were 
similar to those described for qPCR quantification of miRNA expression. Threshold 
values for threshold cycle determination (Ct) were generated automatically by the iQ5 
Optical System Software. Relative miRNA level calculation and statistical analysis were 
performed using the software qBasePlus software (Biogazelle, Gent, Belgium). 
 
3.9) Assessment of Nestin and CD133 expression by Flow Cytometry 
To evaluate the expression of nestin and CD133, U87 cells bounded (U87/CD133+) an 
unbounded (U87/CD133-) to CD133 microbeads, cells were plated into 6-well plates in 
the conditions referred in section 3.3). Since U87/CD133- grow in adherent conditions, in 
the day of flow cytometry experiments these cells were washed twice with PBS, detached 
from plates by exposure to dissociation medium (5 min, 37oC) and washed once more 
with PBS. Both cell types (U87/CD133- and U87/CD133+) were then ressuspended in 
500 µL of cold PBS. After washing, cells were incubated with an antibody for 
CD133/nestin (1:500) for 30 minutes. Since nestin is an intracellular protein, before 
incubation with the antibody against nestin cells were permeabilized with a solution 
containing (PBS 1x, 0,1% triton and 2% FBS). After incubation with the antibodies, cells 
were washed one more time with 500 µL of PBS and finally incubated with alexa-488 
secondary antibody (1:200), if necessary. After a final washing step, cells were analyzed 
in a FACS Calibur flow cytometer (BD, Biosciences). Alexa-488 fluorescence was 
evaluated in the FL-1 channel and a total of 10.000 events were collected for each sample. 
All data were analyzed using the Cell Quest software (BD). 
 
3.10) Laminin coating 
In order to test the behavior of GSC in the presence of laminin, we used laminin coated 
tissue culture plastic (Sigma: L2020). The working laminin solution (10ug/ml in PBS) 
was prepared freshly for each experiment by diluting the stock solution (1mg/ml) 1:100. 
Plates and flasks were covered with the diluted solution and incubated at 37ºC for at least 
3 h. 
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3.11) Preparation of targeted SNALPS and evaluation of cellular assosiation 
Briefly, CTX was modified by the addition of thiol groups upon reaction with freshly 
prepared 2-iminothiolane hydrochloride (2-IT, in HEPES-buffered saline pH 8) at a molar 
ratio of 1:10 (CTX: 2-IT). The reaction occurred under gentle stirring for 1 hour in the 
dark, at room temperature (RT). Thiolated CTX was then coupled to DSPE-PEG-MAL 
micelles, prepared in MES buffer pH 6.5,15 by a thioesther linkage (1:1, CTX: DSPE-
PEG-MAL molar ratio). The coupling reaction was performed overnight (at RT) in the 
dark with gentle stirring. For the NT SNALPs, post insertion was performed with plain 
micelles (without conjugated ligand), which were prepared by adding HEPES-buffered 
saline (pH 8.0) to the DSPE-PEG-MAL micelles. The neutralization of free maleimide 
groups in the micelles was carried out upon incubation with β-mercaptoethanol at a 
maleimide: β-mercaptoethanol molar ratio of 1:5 (0.52:2.6 μmol), under stirring for 30 
minutes (at RT). The insertion of CTX-DSPEPEG-MAL conjugates or plain DSPE-PEG-
MAL micelles onto the preformed liposomes, at 4 mol% (relative to the total lipid 
concentration), was performed upon incubation in a water bath at 39 °C for 16 hours (in 
the dark). Targeted and NT SNALPs were purified by size exclusion chromatography on 
a Sepharose CL-4B column using HEPES-buffered saline (pH 7.4) as running buffer to 
remove non-conjugated micelles and chemical reagents (including unreacted 2-IT and β-
mercaptoethanol) used during SNALPs preparation. To evaluate the extent of cellular 
association of the SNALPs, cells were plated onto 48-well plates at densities of 5 × 104. 
Twenty-four hours after plating, cells were incubated in OptiMEM (Gibco) with targeted 
CTX-coupled or NT liposomes encapsulating FAM-labeled oligonucleotides for 4 hours 
at 37 °C. Subsequently, cells were washed twice with cold PBS (pH 7.4), detached by 
exposure to trypsin (5 minutes, 37 °C) and further washed twice with PBS. Cells were 
then ressuspended in 350 μl of cold PBS and immediately analyzed in a FACS Calibur 
flow cytometer (BD Biosciences, San Jose, CA). FAM fluorescence was evaluated in the 
FL-2 channel and a total of 20,000 events were collected for each sample (unless stated 
otherwise). The data were analyzed by Cell Quest software (BD Biosciences). Trypan 
blue was added (10µL) to quench the fluorescence in the extracellular medium 
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4.1) U87-derived cancer stem cells form neurospheres when cultured under non-
adherent conditions  
Recently, cancer stem cells (CSCs) have emerged as a focus of debate in the development 
of new therapeutic strategies. It seems essential to find differences between CSCs and 
differentiated cancer cells in order to understand why CSCs are more resistant to 
therapies, with the ultimate goal of creating specific treatments that target these cells and 
improve glioblastoma patient survival. In this study we proposed to isolate glioblastoma 
stem cells from a human GBM cell line (U87), using CD133 as a marker, and culture 
these cells in the form of neurospheres. 
 
4.1.1) Isolation of CSCs from U87 cells using the magnetic associated cell sorting 
system 
Our first goal in this project was to isolate CSCs from U87 cells, a well-known human 
GBM cell line. For this purpose, we used magnetic associated cell sorting (MACS) and 
selected CD133 as the specific cell marker to identify the CSC population. During the 
sorting process, U87 cells were incubated with magnetic microbeads that specifically bind 
to epitope 1 of the human CD133 antigen. By applying a magnetic field, it was possible 
to retain the cell population that was bound to the magnetic beads in a column, resulting 
in the separation of these cells from the unbound cells. One portion of bound cells was 
cultured in DMEM/F12 (Invitrogen) supplemented with 1% N2 and 2% B27 (Invitrogen) 
and 20 ng/mL epidermal growth factor and fibroblast growth factor.  
Initially, in order to evaluate the percentage of bound cells that were positive for CD133, 
a small sample of bound-cells was incubated with an antibody associated with a 
fluorophore (PE) against the epitope 2 of the human CD133 antigen. However, as 
illustrated in Figure 9, no significant difference in FL-2 fluorescence was observed 
between cells incubated with the isotype antibody and cells incubated with the anti-
CD133 antibody. To ensure that the presence of the magnetic microbeads was not 
preventing antibody binding to CD133, we repeated the experiment two weeks after cell 
isolation. However, once again, the results showed a lack of labeling for bound cells in 
the presence of the anti-CD133 antibody (data not shown).  
In face of these negative results, we examined whether the chosen antibody was working 
properly. , by employing HT-29 cells, a human colon tumor cell line known to express 
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HT-29 Cells (Isotype) 
HT29 Cells (CD133) 
Figure 10 -– Expression of CD133 marker in HT-29 Cells.  Cells were incubated with an 
antibody associated with a fluorophore (PE) that recognized epitope 2 of the human CD133 
antigen. The percentage of cells expressing CD133 was assessed by flow cytometry   (Grey – 
fluorescence of isotype in HT-29 cells. Green – fluorescence of CD133 in HT-29 cells. 
 
 
CD133 as a positive control for CD133 labeling. Our results, illustrated in Figure 10, 
suggested that the anti-CD133 antibody was not working properly, since no labelling was 
observed in this cell line.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Expression of CD133 marker in U87 Cells bound to microbeads.  Cells 
were incubated with an antibody associated with the fluorophore PE that recognize 
epitope 2 of the human CD133 antigen. The percentage of cells expressing CD133 was 
assessed by flow cytometry   (Purple – fluorescence of isotype in cells bound to 
microbeads and Green - fluorescence of CD133 in cells bound to microbeads) 
 
U87 Bound cells (Isotype) 
U87 Bound cells (CD133) 
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HT-29 Cells (Isotype) 
HT29 Cells (CD133) 
Figure 11 - Expression of CD133 marker plus Alexa-488 in HT-29 Cells. Cells were 
incubated with a primary antibody associated with a fluorophore (PE) that recognize epitope 2 
of the human CD133 antigen and with a secondary Alexa-488 antibody. The percentage of cells 
expressing CD133 was assessed by flow cytometry   (Grey – fluorescence of isotype in HT-29 
cells. Green - fluorescence of CD133 in HT-29 cells). 
After acquiring a new antibody against CD133, our first step was to ensure that this 
antibody was working properly. For this purpose,we incubated HT-29 cells with the new 
CD133 antibody and a secondary Alexa-488 antibody. The number of CD133 positive 
cells was once again assessed by flow cytometry and, as observed in Figure 11), we were 
able to observe that 70% of the cell population expressed CD133. 
 
 
 
 
 
 
 
 
 
 
 
 
 
We then proceeded to the incubation of U87 cells bound to magnetic microbeads with the 
new antibody. The percentage of cells expressing the CD133 marker was assessed by 
flow cytometry based on the Alexa-488 fluorescence (Figure 12). Cells incubated only 
with the secondary antibody Alexa- 488 were used as a control.  Figures 12a and 12c 
show that an average of 40% of the cells bound to microbeads express the CD133 marker. 
Results from experiments in which the unbound cells (CD133-) were subjected to the 
same procedure (Figure 12b) showed that only 8% of this population expressed the 
CD133 marker (Figure 12c).  
To further validate our results in what concerned the cancer stem cell nature of the bound 
cells, we incubated bound and unbound cells with an antibody against nestin, another 
CSC marker, and with an Alexa-488 secondary antibody and the percentage of nestin+ 
cells in each population (bound and unbound cells) was assessed by flow cytometry 
(Figure 13). CD133+/CD133- cells incubated with the secondary antibody Alexa-488 
were used as a control. The population of bound cells showed an average of 75% nestin+ 
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U87 Bounded Cells (Isotype) 
U87 Bounded Cells (CD133) 
 
Figure 12 – Expression of CD133 marker in U87 bound and unbound cells. Bound and 
unbound cells were incubated with CD133 antibody followed by incubation with an alexa-488 anti-
mouse secondary antibody. a) Flow cytometry histogram showing the expression of CD133 in cells 
bounded to microbeads and cultured in DMEMF12 in non-adherent conditions. (Green – 
fluorescence of CD133 in cells bounded to microbeads and Grey - fluorescence of isotype in cells 
bounded to microbeads).  b) Flow cytometry histogram showing the expression of CD133 in cells 
unbounded to microbeads and cultured in DMEM in adherent conditions (Purple – fluorescence of 
CD133 in cells unbounded to microbeads and Green - fluorescence of isotype in cells unbounded 
to microbeads).  c) Percentage of CD133+ cells (Bounden and unbounded cell populations). The 
results are presented as the percentage of CD133+ cells with respect to the control (cells incubated 
with the secondary antibody alexa-488). The results are representative of three independent 
experiments. * – P < 0.05, ** – P < 0.01, *** – P < 0.001 
b 
a 
c 
 
U87 Unbounded Cells (Isotype) 
U87 Unbounded Cells (CD133) 
 
cells (Figure 13a and 13c). As described previously, we also quantified nestin expression 
in CD133- cells to evaluate whether all stem cell-like GBM cells have been isolated 
through the MACS procedure (Figure 13b). The results showed that CD133- cells have 
an average of 30% nestin+ cells (Figure 13c). 
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U87 Bounded Cells (Isotype) 
U87 Bounded Cells (CD133) 
 
Figure 13 – Expression of nestin in bound and unbound cells. Bound and unbound cells were 
incubated with an anti-nestin antibody followed by incubation with the alexa-488 secondary 
antibody. a) Flow cytometry histogram showing the expression of nestin in bound cells cultured in 
DMEMF12 in non-adherent conditions. b) Flow cytometry histogram showing the expression of 
nestin in unbound cells cultured in DMEM in adherent conditions. c) Percentage of nestin+ cells 
(Bound and unbound cell populations). The results are presented as the percentage of CD133+ cells 
with respect to the control (cells incubated with the secondary antibody Alexa-488). The results are 
representative of three independent experiments. * – P < 0.05, ** – P < 0.01, *** – P < 0.001. 
b 
a 
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c d 
b a 
4.1.2) Neurosphere formation by CD133+ cells in DMEMF12 medium 
Our second goal was to and maintain the cancer stem cell properties of CD133+ cells 
during the subsequent experiments. For this purpose, after the isolation of CD133+ cells, 
these cells were cultured in non-adherent conditions, in DMEM/F12 medium 
supplemented with 1% N2 and 2% B27 (Invitrogen) and 20 ng/mL epidermal growth 
factor and fibroblast growth factor. When cultured under these conditions, CD133+ cells 
formed 3-D clusters, called neurospheres.  
Neurospheres were formed over period of two weeks and presented different diameters 
(Figure 14a). No neurosphere formation was observed when CD133- cells were cultured 
in similar conditions (Figure 14b). As shown in Figure 14c and 14d, when cultured in 
adherent conditions with DMEM, both CD133- and CD133+ cells failed to form 
neurospheres, growing at a similar rate. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – Representation of U87/ (CD133+ /CD133-) cells cultured in different 
conditions. a) CD133+ and b) CD133- cells were cultured in DMEM/F12 medium 
supplemented with 2% B27 and 20 ng/mL epidermal growth factor and fibroblast growth 
factor in low-adherence wells. Neurospheres were formed in U87/CD133+ cells two weeks 
after isolation from the U87 cell line. c) CD133+ and d) CD133- cells were cultured in adherent 
conditions with DMEM. No neurospheres were formed in both cell populations in these 
conditions. 
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In conclusion, CD133+ cells isolated from the human glioma cell line U87 present two of 
the major hallmarks of glioblastoma stem cells, which are the surface expression of cancer 
stem cell markers (nestin and CD133) and the ability to grow as neurospheres. 
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4.2) Glioma stem cells show different miRNA profiles when compared to 
differentiated glioma cells. 
MicroRNAs regulate many important processes, such as neuronal differentiation, cell 
growth, proliferation and apoptosis. For this reason, we believe that these small RNA 
molecules can be responsible for the unique characteristics of CSCs. Recent studies have 
shown that miRNAs are important for the high resistance and self-renewal of CSCs. To 
further clarify this assumption, we decided to compare the miRNA profile of glioblastoma 
stem cells (GSCs) with that of non-stem glioblastoma cells, using pre-designed qPCR 
plaques containing primers for 44 miRNAs involved in the cancer biology. 
Using miRNA qRT-PCR arrays, we identified several miRNAs deregulated in glioma 
stem cells (CD133+) with respect to differentiated glioma cells (CD133-). As shown in 
Figure 15, several miRNAs have their expression modified in GSCs, with respect to the 
remaining glioblastoma cell population. 
MicroRNA-128, a well-known miRNA described to be downregulated in glioblastoma, 
was shown to have a very low expression in GSCs. From all tested miRNAs, this was the 
one presenting the largest difference in expression levels between the CD133+ and 
CD133- population. Several other miRNAs had their expression slightly downregulated 
in GSCs, such as miR-130a, miR-1237, miR-210, miR-92a, miR-10b and miR-124 
On the other hand, several miRNAs were shown to be upregulated in GSCs with respect 
to the remaining glioma cell population. The most upregulated miRNAs found in this 
experiment were miR-25, miR-29b, miR-26a, miR-328, miR-101, miR-181a, miR-21, 
miR-27a, miR-25, miR-30a, miR-30c and miR-32. Several of these miRNAs have been 
widely studied in the context of glioblastoma, such as miR-21 and miR-181a, and have 
important roles in tumor growth and cell proliferation. Several other miRNAs presented 
a slightly upregulated expression, including let-7b, miR-130a, miR-149, miR-19b, miR-
34a, miR-9, miR-17, miR-106a, miR-130b, miR-185, miR-20a and miR-93. 
For the other studied miRNAs no difference in their expression levels between GSCs and 
the remaining glioblastoma cell population were observed (data not shown)   
In conclusion, GSCs and the remaining glioblastoma cell population showed different 
miRNA profiles. Among the deregulated miRNAs, miR-128 presented the most altered 
expression, being highly downregulated in GSCs. 
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Figure 15 – MiRNAs expression comparison between GSCs and differentiated 
glioblastoma cells. QPCR quantification of 44 miRNAs in GSCs (CD133+) and glioblastoma 
cells (CD133-) cells was performed using pre-designed miRNA PCR plates. Ct values were 
obtained for each sample (threshold=40 cycles) and normalized to reference gene - snord44; 
Relative miRNA expression values were calculated using the qBasePlus software. MicroRNAs 
not showed either had no different levels of expression between CD133- and CD133+ cells or 
were not detected by qPCR. The results are representative of three independent experiments. 
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4.3) MicroRNA-128 sensitizes U87 to sunitinib-induced cell death 
In the previous section, using pre-designed qPCR plates we were able to determine 
different patterns of miRNA expression between GSCs (CD133+) and the remaining 
glioblastoma cells (CD133-). These results, together with the fact that miRNAs have been 
linked to many disease processes involving stem cells are strong indications that miRNAs 
are important for the unique biology of GSCs.  
Our next goal was to prove that reverting the expression patterns of these miRNAs could 
impair normal GCS function and, consequently, glioblastoma cell growth, setting the 
basis for new therapeutic strategies against this type of cancer.  
Since our results showed that miR-128 exhibited the most altered expression between 
GSCs (CD133+) and the remaining glioblastoma cell population (CD133-), we decided to 
study this miRNA and its targets in more detail. For this purpose, we transfected the whole 
U87 cell population (adherent conditions in DMEM medium) and U87/CD133+ cells 
(neurospheres in DMEM/F12 medium) with miR-128 mimics using Lipofectamine 
RNAiMAX. Lipofectamine RNAiMAXis a commercially available and efficient reagent 
for RNAi delivery to a wide variety of cell lines, stem cells and primary cells. As a control, 
in this experiment, we used non-transfected cells and cells transfected with a scrambled 
mimic (control mimic).  
As shown in Figure 16, miR-128 intracellular levels were successfully increased, in U87 
cells, as assessed by qRT-PCR. Unfortunately, no increase in miR-128 levels were 
observed in neurospheres originated from U87/ CD133+ cultures (data not shown).  
According to the literature, miR-128 has several validated targets (Table 7). Among them, 
BMI-1 (Figure 17b) is one of the most studied and has been linked to glioma stem cell 
resistance to therapy105. To evaluate if miR-128 increase led to a downregulation of BMI-
1 in U87 cells, we performed qRT-PCR experiments and as illustrated in figure 17c BMI-
1 levels are significantly decreased in the U87 human cell line, as compared to controls. 
Taking these results into consideration, we started a series of experiments employing 
sunitinib, in order to evaluate if the cytotoxic effect of this tyrosine kinase inhibitor could 
be potentiated and therefore reduce its therapeutic dose upon combination of this drug 
with miR-128 mimics. Figure 18 shows that miR-128 mimics or sunitinib (15µM) alone 
did not decrease cell viability. However, when combined, miR-128 and sunitinib were 
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able to reduce cell viability to approximately 20%, a result similar to what can be achieved 
with a higher concentration (30 µM) of the drug.  
To overcome the limitation associated with the difficulty of transfecting U87/CD133+ 
cells, we developed two possible strategies to improve transfection. The first strategy was 
based on the use of laminin-coated plates, while the second strategy focused on the use 
of chlorotoxin-coupled stable nucleic acid lipid particles (SNALPs).  
Laminin-coated plates are a new approach to study cancer stem cells. This culture method 
allows cancer stem cells to grow adherent to a surface without losing their stem properties. 
In this regard, laminin plates were prepared by adding laminin to the wells and incubating 
plates at 37ºC for at least for 3 hours. In order to verify if U87/CD133+ cells cultured in 
Figure 16 - Evaluation of miR-128 expression levels in U87 cells following transfection 
with miR-128 mimics. Cells were transfected with miR-128 mimics or control mimics using 
Lipofectamine RNAiMAx for 48 hours. miR-128 levels were quantified by qRT-PCR in a 
StepOnePlus thermocycler (Applied Biosystems) using 96-well microtitre plates and were 
normalized using SNORD 44 as the reference gene. 
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laminin-coated plates maintained their stem potential, we assessed the expression of the 
b) a) 
Figure 17 - Representation of miR-128 targets and BMI-1 expression levels following U87 
transfection with miR-128 mimics. a) MicroRNA-128 validated targets b) PBD 
representation of BMI-1 protein. c)  BMI-1 mRNA expression levels in U87 cell line. Cells 
were transfected with miR-128 mimic using Lipofectamine RNAiMAx and incubated for 48 
hours.BMI-1 mRNA levels were quantified by qPCR in StepOnePlus thermocycler (Applied 
Biosystems) using 96-well microtitre plates and normalized using HPRT as the reference gene. 
Results are representative of three independent experiments. * – P < 0.05, ** – P < 0.01, *** 
– P < 0.001 
c) 
Table 7 – miR-128 Validated targets 
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CD133 marker after 2 weeks, by flow cytometry, following cell incubation with CD133 
antibody plus the secondary antibody Alexa-488. Figure 19 illustrates the obtained results 
and shows that 30% of cells cultured in laminin expressed CD133. 
 
 
 
 
 
Figure 18 – U87 cell viability 48h hours after transfection with miR-128 mimics and/or 
exposure to sunitinib. Cells were transfected with miR-128 mimics using Lipofectamine 
RNAiMAx and incubated for 48 hours. After this period sunitinib was added to the medium 
and cells were further incubated for 24 hours. Cell viability was measured by the alamar blue 
assay 72 hours after transfection. Results were obtained from six independent experiments 
and were normalized to control (non-transfected cells) values. *p<0.05; **p<0.01; ***p 
<0.001. 
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Figure 19 - Expression of CD133 marker in U87/CD133+ cells cultured in laminin-coated 
plates. Following 10 days in culture in laminin-coated plates, CD133+ cells were incubated 
with an antibody against CD133 and with a secondary antibody with alexa-488 associated. 
The percentage of cells expressing CD133 was assessed by flow cytometry. a) Flow cytometry 
histogram showing the expression of CD133 in cells bounded to microbeads, cultured in 
DMEM/F12 in laminin coated plates. Grey – expression of Isotype in cells bounded to 
microbeads and Green - expression of CD133 in cells bounded to microbeads) b) Percentage 
of cells expressing CD133 (Bounded and unbounded to microbeads). Both results were 
normalized with the control (isotope), which corresponds to cells incubated only with the 
secondary antibody alexa-488. The results are representative of independent experiments. * – 
P < 0.05, ** – P < 0.01, *** – P < 0.001. 
 
a) 
b) 
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Another strategy explored in this work to improve the transfection efficiency of GSCs 
involved the use of targeted nanoparticles. Chlorotoxin-coupled stable nucleic acid lipid 
particles (SNALPs) were tested in 2013 in our lab, showing very promising results in 
what concerns the delivery of small interfering RNAs and anti-miRNA oligonucleotides 
to glioma cells111. Chlorotoxin (CTX) was modified by the addition of thiol groups, and 
thiolated CTX was then coupled to DSPE-PEG-MAL micelles through a thioesther 
linkage. U87/CD133+ cells were incubated with chlorotoxin (CTX)-coupled or 
nontargeted (NT) liposomes encapsulating FAM-labeled oligonucleotides, and the 
internalization of these nanoparticles was assessed by flow cytometry (Figure 20). To 
ensure that the detected fluorescence signal was due to the internalized SNALPs trypan 
blue was added to quench the fluorescence in the extracellular medium. Figure 20b shows 
that almost 90% of the cells internalized CTX-SNALPS. On the other hand, only 35% of 
the cells internalized NT-SNALPS. 
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Non-transfected Cells 
Cells transfected with NT-SNALPS 
Cells Transfected with CTX-SNALPS 
Figure 20 – Internalization of SNALPs in U87/CD133+ cells cultured in laminin-coated 
plates. U87/CD133+ cells were incubated with chlorotoxin (CTX)-coupled or nontargeted (NT) 
liposomes encapsulating FAM-labeled oligonucleotides. Particle internalization was assessed by 
flow cytometry. a) Flow cytometry histogram showing the internalization of green – NT-
SNALPS and orange – CTX-SNALPS. b) Percentage of cells presenting internalized NT-
SNALPS or CTX-SNALPS. The results are representative of one experiment, 
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5) Discussion 
MicroRNAs have been associated with various important biological processes over the 
last decade. Regarding glioblastoma, there have been accumulated evidences of miRNA 
importance for cell proliferation, invasion and stem cell renewal. Several studies have 
reported miRNAs to be involved in GBM pathology, affecting multiple processes, 
including proliferation, invasion, migration, angiogenesis, resistance to therapy and 
apoptosis. These small RNA molecules have specific characteristics that make them 
desirable therapeutic targets, including their small size, tissue specificity and multi-
targeting potential. That said, it seems obvious that these RNA molecules can be used as 
both therapeutic agents and therapeutic targets. However, for this to become a reality it is 
necessary to clarify the role of each miRNA in the biology of glioblastoma. 
Another field of interest in glioblastoma research concerns cancer stem cells. Recent 
findings reported the existence cells with stem-like properties among the tumor cell 
population. These cells confer the tumor self-renewable and tumorigenic abilities and 
contribute to tumor resistance. In the last decade, cancer stem cells have also been 
identified in human glioma. However, in glioma, as well as in other cancer types, their 
role is not yet fully understood. It is common knowledge that these cells are able to 
generate the different type of cells that comprise the tumor, sustaining tumorigenesis. 
According to recent studies, GSCs are also more resistant to radio and chemotherapy. 
Taking into consideration their potential to form all kinds of tumor cells, GSCs may be 
responsible for the reappearance of the tumor even after its surgical removal.  Therefore, 
therapies that directly target GSCs are essential for the complete eradication of this type 
of cancer. 
As previously stated, miRNAs can control the translation of most protein-coding genes, 
and are involved in almost every biological pathway, including those connected with GSC 
biology. Over the past decade, numerous studies have helped to clarify the role of miRNA 
in CSCs biology. Nevertheless, further studies are required, including those concerning 
the comparison between miRNA profiles of GSC and the remaining glioblastoma cells. 
These studies can provide important clues to explain why GSC have unique properties, 
such as their high resistant to therapies. Also, taking into account the differences in the 
miRNA profile of GSCs, it would be possible to develop therapies specifically targeting 
these cells, thus expanding and optimizing the therapeutic options for glioblastoma. 
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In the present study, we aimed to compare miRNA profiles of glioma stem cells and 
differentiated glioma cells in order to identify alterations that could explain the different 
characteristics of both types of cells. By performing qRT-PCR arrays against 44 selected 
miRNAs, we showed that GSCs and the remaining glioblastoma cells have different 
miRNA profiles. We obtained evidences that miR-128, in particular, is highly 
downregulated in GSC. Furthermore, we observed that miR-128 overexpression 
sensitized U87 GBM cells to sunitinib-induced cellular death.   
Initially, we isolated GSC from an established glioblastoma cell line (U87 cells) 
employing magnetic associated cell sorting, using CD133, a well-known cancer stem cell 
marker, as a marker for GSCs. We also employed a thoroughly validated protocol for 
GSC growth, using serum-free media supplemented with fibroblast growth factor and 
epidermal growth factor, in order to allow the formation of neurospheres, since the ability 
to form these structures is a major hallmark of GSCs. These conditions greatly reduce 
differentiation and are known to preserve genetic profiles similar to those found in tumors 
removed from patients with an enhanced GSC population. The absence of serum is 
essential since, accordingly with Singh et al112, when exposed to serum, neurospheres 
start to differentiate down the lineage of  the parent tumor.   
Originally, the cells isolated with the CD133 microbeads, although forming neurospheres 
in culture, did not show CD133 labelling when tested with flow cytometry and an 
antibody against the marker (figure 9). We hypothesized that, despite the fact that our 
microbeads and CD133 antibody targeted different epitopes of the CD133 protein, the 
microbeads could cause a modification of the conformation of CD133 or even a stearic 
block effect that prevented the binding of the antibody. In order to investigate these 
possibilities, and the suggestion of the manufacturer, we incubate cells bounded to 
microbeads with CD133 antibody (PE) two weeks of the isolation. This waiting time was 
though to allow microbeads detachment from the cells. However, our results showed 
again no CD133 labeling. Taking these new results into consideration, we decided to test 
the antibody in the HT-29 cell line, which is known to express CD133. Since no CD133 
labeling was also observed in this cell line (figure 10), we concluded that our antibody 
was not working properly and decided to acquire a similar antibody from a different 
brand.  
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Flow cytometry experiments employing the new antibody revealed that at least 37% of 
the microbead-bound cell population was CD133+ (figure 12) and 77% of these 
population was also nestin+ (figure 13). These results, together with the ability to form 
neurospheres (figure 14) allowed us to conclude that the microbead-bounded cell 
population had GSC properties.  
Nevertheless, expression levels of CD133 were not very high (around 37 %), especially 
when compared with the results obtained by Christoph P. Beier and colleagues62 (around 
50 %). Despite that, microbead-bound cells (referred as CD133+ cells to simplify) allowed 
us to mimic the characteristics of GSCs. Since cells were cultured for two weeks before 
the flow cytometry analysis, the low-expression levels of CD133 can be explained by the 
probable differentiation of GSC despite the use of a specific stem cell medium designed 
to repress this process. Contrary to our expectations, CD133- cells showed a small degree 
of labeling for both CD133 (10%) and nestin (40 %) (Figures 12 and 13). Traditionally, 
nestin has been reported for its importance as a neural stem cell marker. However, in the 
past years, expression of nestin was shown not to be stem cell exclusive, but has also been 
associated with general proliferation of progenitor cell populations within 
neoplasms64,113. Interestingly, the work of Li Shen and coleagues113 and Jirina Relichova 
and colleagues114 stated that nestin has and heterogeneous expression pattern in 
glioblastoma cell lines, as observed in our study. Our results can be further justified taking 
into consideration that not all nestin+ cells are also CD133+ and, therefore, nestin+/CD133- 
cells would not be retain in the magnetic field and would be present in  the unbound cell 
population.  
Regarding CD133, this marker has been suggested to be a cancer stem cell marker since 
only CD133+ cells from brain tumor biopsies were able to initiate brain cancer in mouse 
models. However, in 2008, Jian Wang and his group demonstrated that CD133- cells were 
tumorgenic115. With further experiments, these researchers found that tumors derived 
from CD133 negative cells contained 1–5% CD133 positive cells115. These results 
suggest that even using different isolation methods, there is always the possibility that 
some CD133+ cells escape the separation protocols. 
 As anticipated, miRNA profiles of CD133+ and CD133- cells showed significant and 
interesting differences (figure 15).  MicroRNA-128, in particular, was found to be 
downregulated in CD133+ cells when compared to CD133- cells. This microRNA had 
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previously been reported to be downregulated in GBM. However, our results show that 
its expression is even more downregulated in CD133+, suggesting that the absence of this 
miRNA may be important to maintain cancer stem cell properties. E2F3a, a transcription 
factor that induces the expression of genes involved in cell cycle progression, and Bmi-
1, a member of the polycomb repressor complex (PRC1) are two of the main targets of 
miR-12835,88,91.  
Our results fully agree with the data obtained by Pierpaolo Peruzz and colleagues105 in 
2013, where they showed that miR-128 is an important suppressor of PRC activity in 
glioma stem cells, and its absence occurs early during gliomagenesis. They showed that 
besides Bmi-1, a component of PRC1, miR-128 also targets the mRNA of SUZ12, a key 
component of PRC2. Also in line with our results is the work performed in 2008 by Jakub 
Godlewski and colleagues. They focused their research on the effects of miR-128 on 
glioma self-renewal, which is thought to be a characteristic of GBM stem-like cells 
regulated by Bmi-1. The authors demonstrated that miR-128 specifically blocked glioma 
self-renewal, in a way consistent with Bmi-1 down-regulation. Altogether, these results 
suggest that miR-128 absence is essential for GBM self-renewal and resistance to therapy. 
Taking this into account, upregulating miR-128 could be a promising therapeutic strategy 
for GBM.  
To shed some light on the role of miR-128 in GSCs and GBM biology, we tried to deliver 
miR-128 mimics to U87 cells and to U87/CD133+ cells. We were able to increase miR-
128 expression (figure 16) and decrease the mRNA levels for BMI-1 (figure 17) in U87 
cells, but unfortunately, we were unable to do the same in the neurospheres present in 
U87/ CD133+ cultures.  
Figure 18 shows that miR-128 overexpression combined with sunitinib (15µM) was able 
to reduce U87 cell viability to approximately 20%. This result is similar to that obtained 
with the double concentration of sunitinib (30µM), and is in agreement with the results 
obtained by Pedro M. Costa et al116. These data suggest that miR-128 overexpression 
sensitized U87 cells to sunitinib-induced cell death and prove that it is possible achieve a 
significant reduction in cellular viability employing a lower concentration of the drug, 
which would probably result in a reduction in the expected side effects.  
As stated previously, miRNAs are differentially expressed in normal tissues and cancers, 
and aberrant miRNA expression is associated with GBM tumorigenesis. For this reason, 
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these small RNA molecules are very attractive therapeutic targets for GBM. MicroRNA-
128 has been the subject of several studies since it is downregulated in several tumor 
types, such as the breast cancer and GBM. In 2011, a group of researchers led by Yinghua 
Zhu showed similar results to those obtained in the present study, but in breast cancer. By 
transfecting breast tumor–initiating cells (BT-IC) with miR-128, they sensitized BT-ICs 
to the DNA-damaging effects of doxorubicin, illustrating the therapeutic potential of this 
miRNA. Those findings indicated that Bmi-1 (validated target of miR-128) 
overexpression is a stem cell–like feature underlying chemotherapy resistance in these 
cells117. 
Other reports found in the literature focus in several other miRNAs found to be differently 
expressed in CD133+ cells in this study. In the work develop by Zhen Fu et al and 
coworkers13, miR-181b was shown to function as a tumor suppressor, repressing 
proliferation and reducing chemoresistance to temozolomide in GSCs. The results 
presented by the authors suggested that the miR-181b could potentially serve as a 
therapeutic agent for eradicating glioma stem cells118.  
In the same line of research, focusing on miRNA-mediated sensitization of tumor cells, 
our group has also shown interesting results concerning miR-21.  Contrary to what was 
done in the studies mentioned above, we have used anti-miR-21 oligonucleotides to 
sensitize U87 cells to sunitinib through miR-21 silencing116. All this studies reflect the 
fact that miRNA-based modulation strategies can also be used to sensitized tumor cells 
to other treatments and to potentiate the effect of conventional therapies.  
In what concerns our inability to modulate miR-128 and BMI-1 expression in U87/ 
CD133+, these results can be explained by the inherent characteristics of neurosphere 
cultures. Neurospheres are characterized by a condensed structure of its cells, which can 
hinder the diffusion of molecules to the innermost cells119. This characteristic of 
neurosphere cultures brings yet another important issue. When neurospheres grow larger 
the percentage of stem-like cells decreases due to poor diffusion of growth factors and an 
increase in central hypoxia119. Since neurosphere culture presents all this associated 
limitations, other means for the study and transfection of cancer stem cells are urgently 
required. In our work we tested two preliminary approaches aiming at improving the 
transfection of glioma stem cells, based on the use of 1) laminin-coated plates to allow 
monolayer GSC culture and 2) CTX-SNALP to improve GSC transfection. 
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Realizing the need for new cancer stem cell culture options, Steven M. Pollard and 
colleagues120 first cultured these cells in laminin-coated plates, in order to promote 
adherence without losing stemness. The adherent GSCs were more homogeneous than 
neurosphere cultures, and presented high expression of GSC genes, such as Sox2, Nestin, 
CD133 and CD44. In our study we showed that laminin cultured cells maintain CD133 
labeling (figure 19). Culture on an adherent laminin surface allows for a more uniform 
exposure to growth factors and oxygen. Decreased cell to cell contact and integrin/laminin 
signaling may also maintain the stem-cell-like state by limiting differentiation 
signaling120. Taking into account that glioma stem cells in laminin-coated wells stay 
adherent and that lipoplexes and other non-viral delivery systems have the tendency to 
become deposit due to gravity at the surface of exposed cells, this culture method could 
help improve transfection of GSCs in vitro and to study the therapeutic efficacy of 
miRNA modulation in these cells. 
Stable nucleic acid lipid particles (SNALPs) were shown111 to be very efficient to deliver 
small interfering RNAs (siRNAs) to different types of cancer cells. In SNALPs, the 
siRNA is surrounded by a lipid bilayer containing a mixture of cationic and fusogenic 
lipids. These complex liposomes are quite versatile and can be coupled with peptides to 
mediate specific delivery to tumor cells, taking advantage of overexpressed tumor 
receptors. In this regard, our group has developed CTX-coupled SNALPs to promote both 
siRNA or anti-miRNA oligonucleotide delivery to glioblastoma cells111. Chlorotoxin was 
reported to bind to matrix metalloproteinase-2, which is upregulated in gliomas and 
poorly expressed in normal tissues. Taking this into account, this scorpion-derived 
peptide can be used to enhance SNALP targeting to GBM cells. In the study by Pedro M 
Costa and colleagues111, the authors showed that CTX-coupled SNALPs enhance the 
delivery of anti-miR-21 oligonucleotides to different glioma cell lines and intracranial 
tumors, with reduced affinity for non-cancer cells111. In our study, we were able to 
increase SNALP internalization in U87/CD133+ cells by 55% using CTX as a ligand 
(figure 20), suggesting that this could be an interesting strategy to mediate the microRNA 
modulation in GSCs cells.  
Overall, our results reflect the current belief that miRNAs play an important role in GBM 
and that miRNA-modulation strategies, alone or in combination with conventional 
therapies, may allow a significant improvement in patient care in the a near future. 
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6) Conclusions  
  
 The results obtained in this work and their implications in the field of gene therapy 
for glioblastoma multiforme (GBM) and glioma stem cells (GSCs) led to several 
interesting conclusions that are summarized below. 
 
 Glioma stem cells isolated from the U87 cell line (U87/CD133+ cells) and 
maintained in culture in non-adherent conditions, express both nestin and CD133 
two weeks after isolation. U87/CD133+ cells, contrarily to U87/CD133- cells, are 
able to form neurospheres in these conditions.  
 
 When compared directly, U87/CD133+ and U87/CD133- cells show different 
miRNA expression profiles. MiR-128 was shown to be downregulated in GSCs, 
and, importantly, overexpression of miR-128 was able to sensitize U87 cells to 
sunitinib-induced cell death. 
 
 Laminin-coated plates, due to its adherent capacity, can be an interesting new 
cancer stem cell culture method for miRNA transfection. Moreover, CTX-
SNALPs showed increased internalization compared to NT-SNALPs and can be 
another strategy to improve the delivery of small interfering RNAs and miRNA 
mimics to GSCs. 
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